MCID: LNG032
MIFTS: 95

Lung Cancer malady

Categories: Genetic diseases (common), Cancer diseases, Respiratory diseases

Aliases & Classifications for Lung Cancer

About this section

Aliases & Descriptions for Lung Cancer:

Name: Lung Cancer 49 10 22 23 12 67 35 2
Non-Small Cell Lung Carcinoma 32 10 12 65
Lung Carcinoma 10 22 47 12
Adenocarcinoma of Lung, Response to Tyrosine Kinase Inhibitor in 49 11
Nonsmall Cell Lung Cancer, Somatic 49 11
Lung Cancer, Protection Against 49 24
Adenocarcinoma of Lung, Somatic 49 22
Carcinoma, Non-Small-Cell Lung 36 24
Malignant Neoplasm of Lung 23 65
Nonsmall Cell Lung Cancer 49 67
Lung Cancer, Somatic 49 22
Carcinoma of Lung 10 65
Lung Neoplasms 23 65
Cancer Lung 47 24
Nsclc 10 47
Nonsmall Cell Lung Cancer, Response to Tyrosine Kinase Inhibitor in 49
Bronchioloalveolar Adenocarcinoma 65
 
Carcinoma Non-Small Cell Lung 47
Non-Small Cell Lung Cancer 10
Malignant Tumor of Lung 23
Alveolar Cell Carcinoma 67
Adenocarcinoma of Lung 67
Lung Malignant Tumors 23
Respiratory Carcinoma 23
Malignant Lung Tumor 23
Pulmonary Neoplasms 23
Pulmonary Carcinoma 23
Cancer of the Lung 23
Cancer of Bronchus 23
Lung Malignancies 23
Pulmonary Cancer 23
Cancer of Lung 10
Lung Neoplasm 10
Lncr 67

Characteristics:

HPO:

61
lung cancer:
Inheritance: autosomal recessive inheritance


Classifications:



External Ids:

OMIM49 211980
Disease Ontology10 DOID:1324, DOID:3905, DOID:3908
NCIt42 C4878, C2926
UMLS65 C0024624, C0153491, C0153492 C0153493, C0684249, C0007131, C0242379, more

Summaries for Lung Cancer

About this section
MedlinePlus:35 Lung cancer is one of the most common cancers in the world. it is a leading cause of cancer death in men and women in the united states. cigarette smoking causes most lung cancers. the more cigarettes you smoke per day and the earlier you started smoking, the greater your risk of lung cancer. high levels of pollution, radiation and asbestos exposure may also increase risk. common symptoms of lung cancer include a cough that doesn't go away and gets worse over time constant chest pain coughing up blood shortness of breath, wheezing, or hoarseness repeated problems with pneumonia or bronchitis swelling of the neck and face loss of appetite or weight loss fatigue doctors diagnose lung cancer using a physical exam, imaging, and lab tests. treatment depends on the type, stage, and how advanced it is. treatments include surgery, chemotherapy, radiation therapy, and targeted therapy. targeted therapy uses substances that attack cancer cells without harming normal cells. nih: national cancer institute

MalaCards based summary: Lung Cancer, also known as non-small cell lung carcinoma, is related to breast cancer and situs inversus, and has symptoms including alveolar cell carcinoma, snoring and coughing. An important gene associated with Lung Cancer is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways are Immune System and Pathways in cancer. The drugs cyclophosphamide and cisplatin have been mentioned in the context of this disorder. Affiliated tissues include the lung, lung and brain, and related mouse phenotypes are cellular and mortality/aging.

Disease Ontology:10 A respiratory system cancer that is located in the lung.

Genetics Home Reference:23 Lung cancer is a disease in which certain cells in the lungs become abnormal and multiply uncontrollably to form a tumor. Lung cancer may or may not cause signs or symptoms in its early stages. Some people with lung cancer have chest pain, frequent coughing, breathing problems, trouble swallowing or speaking, blood in the mucus, loss of appetite and weight loss, fatigue, or swelling in the face or neck. Lung cancer occurs most often in adults in their sixties or seventies. Most people who develop lung cancer have a history of long-term tobacco smoking; however, the condition can occur in people who have never smoked.

OMIM:49 Lung cancer is the leading cause of cancer deaths in the U.S. and worldwide. The 2 major forms of lung cancer are... (211980) more...

CDC:2 Lung cancer is the leading cause of cancer death and the second most common cancer among both men and women in the United States.

UniProtKB/Swiss-Prot:67 Lung cancer: A common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.

Wikipedia:68 Lung cancer, also known as lung carcinoma, is a malignant lung tumor characterized by uncontrolled cell... more...

Related Diseases for Lung Cancer

About this section

Diseases in the Lung Cancer family:

Lung Benign Neoplasm Lung Carcinoma in Situ
Lung Cancer, Egfr-Related Lung Cancer, Gstm1-Related

Diseases related to Lung Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 471)
idRelated DiseaseScoreTop Affiliating Genes
1breast cancer32.4CASP8, EGFR, ERBB2, GNL3, KRAS, MUT
2situs inversus31.5EGFR, ERBB2
3sclerosing hemangioma31.5BRAF, EGFR, ERBB2
4selection of therapeutic option in non-small cell lung carcinoma12.3
5lung cancer susceptibility 312.1
6lung cancer susceptibility 512.1
7lung cancer susceptibility 411.9
8lung cancer susceptibility 211.9
9hilar lung neoplasm11.9
10lung cancer, egfr-related11.9
11lung cancer, gstm1-related11.9
12non-small cell lung cancer, childhood11.8
13small cell lung cancer, childhood11.8
14small cell lung cancer, adult11.8
15muscular dystrophy-dystroglycanopathy , type a, 211.7BRAF, EGFR, ERBB2, KRAS, PIK3CA, RASSF1
16eccrine papillary adenocarcinoma11.6EGFR, ERBB2, KRAS, PIK3CA
17cavernous hemangioma11.6EGFR, ERBB2, KRAS, PIK3CA
18ovary epithelial cancer11.6EGFR, ERBB2, KRAS, PIK3CA
19ovarian wilms' cancer11.6EGFR, ERBB2, KRAS, PIK3CA
20tracheal lymphoma11.6EGFR, ERBB2, KRAS, PIK3CA
21tenosynovitis of foot and ankle11.5EGFR, ERBB2, KRAS, PIK3CA
22hartnup disorder11.5EGFR, ERBB2, KRAS, RASSF1
23cell type cancer11.5EGFR, ERBB2, KRAS, PIK3CA
24zimmermann-laband syndrome 211.5EGFR, ERBB2, PIK3CA, RASSF1
25neuromuscular disease11.5ERBB2, KRAS, PIK3CA
26bacterial exanthem11.5EGFR, ERBB2, KRAS
27anterior horn cell disease11.5EGFR, KRAS, PIK3CA
28prostate neuroendocrine neoplasm11.5BRAF, EGFR, ERBB2, KRAS
29pyometritis11.4BRAF, EGFR, KRAS
30lupus erythematosus11.4CASP8, EGFR, ERBB2
31pancreatic somatostatinoma11.4EGFR, ERBB2, KRAS
32flat ductal epithelial atypia11.4EGFR, ERBB2
33cryptosporidiosis-chronic cholangitis-liver disease syndrome11.4EGFR, KRAS
34brachyolmia11.4EGFR, ERBB2, KRAS
35bicervical bicornuate uterus and blind hemivagina11.4EGFR, KRAS
36thyroid carcinoma with thyrotoxicosis11.4BRAF, ERBB2
37adenofibroma11.3EGFR, ERBB2
38cataract-intellectual disability-hypogonadism syndrome11.3BRAF, KRAS
39proctitis11.3EGFR, ERBB2, KRAS
40orofaciodigital syndrome iv11.3CASP8, FASLG, KRAS
41her2-receptor positive breast cancer11.3EGFR, ERBB2
42frontotemporal dementia and/or amyotrophic lateral sclerosis 411.3BRAF, PIK3CA, RASSF1
43thyroid cancer, childhood11.3BRAF, PIK3CA
44eccrine papillary adenoma11.2BRAF, KRAS
45adrenal cortical carcinoma11.2CASP8, EGFR, ERBB2, FASLG, GNL3, KRAS
46lung squamous cell carcinoma11.2
47spondylitis11.2EGFR, ERBB2
48gingival recession11.2EGFR, ERBB2, IRF1, KRAS
49cervical cancer, somatic11.2EGFR, ERBB2, GNL3, KRAS, RASSF1
50cervical non-keratinizing squamous cell carcinoma11.1EGFR, PIK3CA

Graphical network of the top 20 diseases related to Lung Cancer:



Diseases related to lung cancer

Symptoms for Lung Cancer

About this section

Symptoms by clinical synopsis from OMIM:

211980

Clinical features from OMIM:

211980

HPO human phenotypes related to Lung Cancer:

id Description Frequency HPO Source Accession
1 alveolar cell carcinoma HP:0006519

UMLS symptoms related to Lung Cancer:


snoring, coughing, hemoptysis, dyspnea

Drugs & Therapeutics for Lung Cancer

About this section

FDA approved drugs:

(show all 28)
id Drug Name Active Ingredient(s)15 Company Approval Date
1
Abraxane15 41 PACLITAXEL Celgene October 2012
FDA Label: Abraxane
Disease/s that Drug Treats:non-small cell lung cancer
Indications and Usage:15 ABRAXANE is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, after failure of combination chemotherapyfor metastatic disease or relapse within 6 months of adjuvantchemotherapy. Prior therapy should have included an anthracyclineunless clinically contraindicated. (1.1) Locally advanced or metastatic non-small cell lung cancer (NSCLC),as first-line treatment in combination with carboplatin, in patients whoare not candidates for curative surgery or radiation therapy. (1.2) Metastatic adenocarcinoma of the pancreas as first-line treatment, incombination with gemcitabine. (1.3)
DrugBank Targets:13 1. Apoptosis regulator Bcl-2;;2. Tubulin beta-1 chain;;3. Nuclear receptor subfamily 1 group I member 2;;4. Microtubule-associated protein 4;;5. Microtubule-associated protein 2; ;6. Microtubule-associated protein tau
Mechanism of Action:15 
Target: microtubule
Action: inhibitor
FDA: ABRAXANE is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubulesby preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubulenetwork that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or “bundles” ofmicrotubules throughout the cell cycle and multiple asters of microtubules during mitosis.
2
Alimta15 41 PEMETREXED (also Pemetrexed Disodium) Eli Lilly February 2004
FDA Label: Alimta
Disease/s that Drug Treats:Mesothelioma
Indications and Usage:15 ALIMTA® is a folate analog metabolic inhibitor indicated for: Locally Advanced or Metastatic Nonsquamous Non-Small CellLung Cancer: Initial treatment in combination with cisplatin. (1.1) Maintenance treatment of patients whose disease has notprogressed after four cycles of platinum-based first-linechemotherapy. (1.2) After prior chemotherapy as a single-agent. (1.3) Mesothelioma: in combination with cisplatin. (1.4)Limitations of Use: ALIMTA is not indicated for the treatment of patients withsquamous cell non-small cell lung cancer. (1.5)
DrugBank Targets:13 1. Thymidylate synthase;2. Bifunctional purine biosynthesis protein PURH;3. Dihydrofolate reductase;4. Trifunctional purine biosynthetic protein adenosine-3
Mechanism of Action:15 
Target: folic acid/ thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase
Action: antagonist/ inhibitor
FDA: ALIMTA, pemetrexed for injection, is a folate analog metabolic inhibitor that exerts its action by disrupting folatedependentmetabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibitsthymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT),which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides.Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate bindingprotein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzymefolylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT.Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, is thought to occur to alesser extent, in normal tissues. Polyglutamated metabolites are thought to have an increased intracellular half-liferesulting in prolonged drug action in malignant cells.
3
Avastin15 41 BEVACIZUMAB Genentech July 2009
FDA Label: Avastin
Disease/s that Drug Treats:renal cell carcinoma & Colorectal Cancer
Indications and Usage:15 Avastin is a vascular endothelial growth factor-specific angiogenesisinhibitor indicated for the treatment of: Metastatic colorectal cancer, with intravenous 5-fluorouracil-basedchemotherapy for first- or second-line treatment. (1.1) Metastatic colorectal cancer, with fluoropyrimidine- irinotecan- orfluoropyrimidine-oxaliplatin-based chemotherapy for second-linetreatment in patients who have progressed on a first-line Avastincontainingregimen. (1.1) Non-squamous non-small cell lung cancer, with carboplatin and paclitaxelfor first line treatment of unresectable, locally advanced, recurrent ormetastatic disease. (1.2) Glioblastoma, as a single agent for adult patients with progressive diseasefollowing prior therapy. (1.3)-Effectiveness based on improvement in objective response rate. No dataavailable demonstrating improvement in disease-related symptoms orsurvival with Avastin. Metastatic renal cell carcinoma with interferon alfa (1.4) Cervical cancer, in combination with paclitaxel and cisplatin or paclitaxeland topotecan in persistent, recurrent, or metastatic disease. (1.5) Platinum-resistant recurrent epithelial ovarian, fallopian tube or primaryperitoneal cancer, in combination with paclitaxel, pegylated liposomaldoxorubicin or topotecan (1.6) Limitation of Use: Avastin is not indicated for adjuvant treatment of coloncancer. (1.1)
DrugBank Targets:13 1. Vascular endothelial growth factor A;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10. Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:15 
Target: VEGF
Action: inhibitor
FDA: Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR)697 on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial698 cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration699 of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction700 of microvascular growth and inhibition of metastatic disease progression
4
Cyramza15 41 RAMUCIRUMAB Eli Lilly April 2014
FDA Label: Cyramza
Disease/s that Drug Treats:gastric cancer
Indications and Usage:15 CYRAMZA® is a human vascular endothelial growth factor receptor 2antagonist indicated as a single agent or in combination with paclitaxel, for treatmentof advanced gastric or gastro-esophageal junctionadenocarcinoma, with disease progression on or after priorfluoropyrimidine- or platinum-containing chemotherapy. (1.1) in combination with docetaxel, for treatment of metastatic nonsmallcell lung cancer with disease progression on or afterplatinum-based chemotherapy. Patients with EGFR or ALKgenomic tumor aberrations should have disease progression onFDA-approved therapy for these aberrations prior to receivingCYRAMZA. (1.2) in combination with FOLFIRI, for the treatment of metastaticcolorectal cancer with disease progression on or after priortherapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.(1.3)
DrugBank Targets: -
Mechanism of Action:15 
Target: ligand-stimulated activation of VEGF Receptor 2
Action: inhibitor
FDA: Ramucirumab is a vascular endothelial growth factor receptor 2 antagonist that specifically binds VEGF Receptor2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligandstimulatedactivation of VEGF Receptor 2, thereby inhibiting ligand-induced proliferation, and migration of humanendothelial cells. Ramucirumab inhibited angiogenesis in an in vivo animal model.
5
Gemzar15 41 GEMCITABINE HYDROCHLORIDE Eli Lilly May 1996
FDA Label: Gemzar
Disease/s that Drug Treats:pancreatic cancer/Lung cancer
Indications and Usage:15 Gemzar® is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovariancancer that has relapsed at least 6 months after completion of platinumbasedtherapy (1.1) in combination with paclitaxel, for first-line treatment of metastaticbreast cancer after failure of prior anthracycline-containing adjuvantchemotherapy, unless anthracyclines were clinically contraindicated(1.2) in combination with cisplatin for the treatment of non-small cell lungcancer (1.3) as a single agent for the treatment of pancreatic cancer (1.4)
DrugBank Targets:13 1. DNA;2. Ribonucleoside-diphosphate reductase large subunit;3. Thymidylate synthase;4. UMP-CMP kinase
Mechanism of Action:15 
Target: ribonucleotide reductase
Action: inhibitor
FDA: Gemcitabine kills cells undergoing DNA synthesis and blocks the progression of cells through the G1/S-phase boundary.Gemcitabine is metabolized by nucleoside kinases to diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. Gemcitabinediphosphate inhibits ribonucleotide reductase, an enzyme responsible for catalyzing the reactions that generate deoxynucleosidetriphosphates for DNA synthesis, resulting in reductions in deoxynucleotide concentrations, including dCTP. Gemcitabinetriphosphate competes with dCTP for incorporation into DNA. The reduction in the intracellular concentration of dCTP by the actionof the diphosphate enhances the incorporation of gemcitabine triphosphate into DNA (self-potentiation). After the gemcitabinenucleotide is incorporated into DNA, only one additional nucleotide is added to the growing DNA strands, which eventually results inthe initiation of apoptotic cell death.
6
Gilotrif15 41 AFATINIB DIMALEATE Boehringer Ingelheim July 2013
FDA Label: Gilotrif
Disease/s that Drug Treats:metastatic non-small cell lung cancer with EGFR mutations
Indications and Usage:15 GILOTRIF is a kinase inhibitor indicated for the first-line treatment ofpatients with metastatic non-small cell lung cancer (NSCLC) whose tumorshave epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21(L858R) substitution mutations as detected by an FDA-approved test (1)Limitation of Use: Safety and efficacy of GILOTRIF have not beenestablished in patients whose tumors have other EGFR mutations (1)
DrugBank Targets:13 1. Epidermal growth factor receptor;2. Receptor tyrosine-protein kinase erbB-2;3. Receptor tyrosine-protein kinase erbB-4
Mechanism of Action:15 
Target: tyrosine kinase autophosphorylation
Action: inhibitor
FDA: Afatinib covalently binds to the kinase domains of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4) andirreversibly inhibits tyrosine kinase autophosphorylation, resulting in downregulation of ErbB signaling.Afatinib demonstrated inhibition of autophosphorylation and in vitro proliferation of cell lines expressing wildtypeEGFR or those expressing selected EGFR exon 19 deletion mutations or exon 21 L858R mutations,including some with a secondary T790M mutation, at afatinib concentrations achieved, at least transiently, inpatients. In addition, afatinib inhibited in vitro proliferation of cell lines overexpressing HER2.Treatment with afatinib resulted in inhibition of tumor growth in nude mice implanted with tumors eitheroverexpressing wild type EGFR or HER2 or in an EGFR L858R/T790M double mutant model.
7
Hycamtin15 41 TOPOTECAN HYDROCHLORIDE GlaxoSmithKline/ SmithKline Beecham October 2007/ May 1996
FDA Label: Hycamtin
Disease/s that Drug Treats:small cell lung cancer/ ovarian cancer
Indications and Usage:15 HYCAMTIN for injection is a topoisomerase inhibitor indicated for: metastatic carcinoma of the ovary after disease progression on or afterinitial or subsequent chemotherapy. (1.1) small cell lung cancer platinum-sensitive disease in patients whoprogressed after first-line chemotherapy. (1.2) combination therapy with cisplatin for Stage IV-B, recurrent, orpersistent carcinoma of the cervix which is not amenable to curativetreatment. (1.3)
DrugBank Targets:13 1. DNA topoisomerase 1;2. DNA topoisomerase I, mitochondrial;3. DNA
Mechanism of Action:15 
Target: topoisomerase I
Action: inhibitor
FDA: Topoisomerase I relieves torsional strain in DNA by inducing reversible single-strand breaks.Topotecan binds to the topoisomerase I-DNA complex and prevents re-ligation of these singlestrandbreaks. The cytotoxicity of topotecan is thought to be due to double-strand DNA damageproduced during DNA synthesis, when replication enzymes interact with the ternary complexformed by topotecan, topoisomerase I, and DNA. Mammalian cells cannot efficiently repairthese double-strand breaks.
8
Iressa15 41 GEFITINIB AstraZeneca May 2003
FDA Label: Iressa
Disease/s that Drug Treats:Non-Small-Cell Lung Cancer
Indications and Usage:15 IRESSA is indicated as monotherapy for the continued treatment of patients with locally advanced ormetastatic non-small cell lung cancer after failure of both platinum-based and docetaxelchemotherapies who are benefiting or have benefited from IRESSA.In light of positive survival data with other agents including another oral EGFR inhibitor, physiciansshould use other treatment options in advanced non-small cell lung cancer patient populations whohave received one or two prior chemotherapy regimens and are refractory or intolerant to their mostrecent regimen. The effectiveness of IRESSA was initially based on objective response rates (see CLINICALPHARMACOLOGY-Clinical Studies section). Subsequent studies intended to demonstrate anincrease in survival have been unsuccessful. Specifically, results from a large placebo-controlledrandomized trial in patients with advanced NSCLC who progressed while receiving or within 90 daysof the last dose of chemotherapy or were intolerant to the most recent prior chemotherapy regimen, didnot show an improvement in survival (see CLINICAL PHARMACOLOGY- Clinical Studiessection).Results from two large, controlled, randomized trials in first-line treatment of non-small cell lungcancer showed no benefit from adding IRESSA to doublet, platinum-based chemotherapy.
DrugBank Targets:13 1. Epidermal growth factor receptor
Mechanism of Action:15 
Target: EGFR tyrosine kinase and other tyrosine kinases
Action: inhibitor
FDA: The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinibinhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembranecell surface receptors, including the tyrosine kinases associated with the epidermal growth factorreceptor (EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells.No clinical studies have been performed that demonstrate a correlation between EGFR receptorexpression and response to gefitinib.
9
Keytruda15 41 PEMBROLIZUMAB Merck September 2014
FDA Label: Keytruda
Disease/s that Drug Treats:unresectable or metastatic melanoma
Indications and Usage:15 KEYTRUDA is a human programmed death receptor-1 (PD-1)-blockingantibody indicated for the treatment of patients with unresectable ormetastatic melanoma and disease progression following ipilimumaband, if BRAF V600 mutation positive, a BRAF inhibitor.This indication is approved under accelerated approval based on tumorresponse rate and durability of response. An improvement in survivalor disease-related symptoms has not yet been established. Continuedapproval for this indication may be contingent upon verification anddescription of clinical benefit in the confirmatory trials. (1)
DrugBank Targets:13 1. Programmed cell death protein 1
Mechanism of Action:15 
Target: PD-1 receptor
Action: blocks interaction withPD-L1 and PD-L2
FDA: Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cellproliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction withPD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including theanti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted indecreased tumor growth.
10
Neutroval15 tbo-filgrastim Teva Pharmaceutical August 2012
FDA Label: -
Disease/s that Drug Treats:severe chemotherapy-induced neutropenia
Indications and Usage:15 -
DrugBank Targets:13 1. Granulocyte colony-stimulating factor receptor;2. Neutrophil elastase
Mechanism of Action:15 
Target: G-CSF receptors
Action: stimulates proliferation of neutrofils
FDA: -
11
Opdivo15 41 NIVOLUMAB Bristol-Myers Squibb March 2015/ December 2014
FDA Label: Opdivo
Disease/s that Drug Treats:metastatic squamous non-small cell lung cancer/ unresectable or metastatic melanoma
Indications and Usage:15 OPDIVO is a programmed death receptor-1 (PD-1) blocking antibodyindicated for the treatment of patients with: unresectable or metastatic melanoma and disease progression followingipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. (1.1)This indication is approved under accelerated approval based on tumorresponse rate and durability of response. Continued approval for thisindication may be contingent upon verification and description of clinicalbenefit in the confirmatory trials. (1.1, 14.1) metastatic squamous non-small cell lung cancer with progression on orafter platinum-based chemotherapy. (1.2)
DrugBank Targets:13 1. Programmed cell death protein 1
Mechanism of Action:15 
Target: PD-1 receptor
Action: blocker of interaction with PD-L1 and PD-L2
FDA: Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibitsT-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in sometumors and signaling through this pathway can contribute to inhibition of active T-cell immunesurveillance of tumors. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibodythat binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1pathway-mediated inhibition of the immune response, including the anti-tumor immuneresponse. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumorgrowth.
12
Photodynamic Therapy (& Photofrin)15 PORFIMER SODIUM Sanofi-aventis January, 1996
Disease/s that Drug Treats:esophageal cancer
Indications and Usage:15 PHOTOFRIN is a photodynamic therapy drug indicated for:Esophageal Cancer (1.1) Palliation of patients with completely obstructing esophageal cancer, or ofpatients with partially obstructing esophageal cancer who, in the opinion oftheir physician, cannot be satisfactorily treated with Nd:YAG laser therapyEndobronchial Cancer (1.2) Treatment of microinvasive endobronchial non-small-cell lung cancer(NSCLC) in patients for whom surgery and radiotherapy are not indicated Reduction of obstruction and palliation of symptoms in patients withcompletely or partially obstructing endobronchial NSCLCHigh-Grade Dysplasia in Barrett’s Esophagus (1.3) Ablation of high-grade dysplasia (HGD) in Barrett’s esophagus (BE)patients who do not undergo esophagectomy
DrugBank Targets: -
Mechanism of Action:15 
Target: tumor cells
Action: prpagates radical reactions
FDA: Cellular damage caused by photodynamic therapy (PDT) withPHOTOFRIN is a consequence of the propagation of radical reactions.Radical initiation may occur after porfimer sodium absorbs light to forma porphyrin excited state. Spin transfer from porfimer sodium tomolecular oxygen may then generate singlet oxygen. Subsequentradical reactions can form superoxide and hydroxyl radicals. Tumordeath also occurs through ischemic necrosis secondary to vascularocclusion that appears to be partly mediated by thromboxane A2 release.As opposed to a thermal effect, the laser treatment with porfimersodium induces a photochemical effect. The necrotic reaction andassociated inflammatory responses may evolve over several days.
13
Photofrin15 PORFIMER SODIUM QLT January 1998
FDA Label: Photofrin
Disease/s that Drug Treats:Non-small cell lung cancer
Indications and Usage:15 PHOTOFRIN is a photodynamic therapy drug indicated for:Esophageal Cancer (1.1) Palliation of patients with completely obstructing esophageal cancer, or ofpatients with partially obstructing esophageal cancer who, in the opinion oftheir physician, cannot be satisfactorily treated with Nd:YAG laser therapyEndobronchial Cancer (1.2) Treatment of microinvasive endobronchial non-small-cell lung cancer(NSCLC) in patients for whom surgery and radiotherapy are not indicated Reduction of obstruction and palliation of symptoms in patients withcompletely or partially obstructing endobronchial NSCLCHigh-Grade Dysplasia in Barrett’s Esophagus (1.3) Ablation of high-grade dysplasia (HGD) in Barrett’s esophagus (BE)patients who do not undergo esophagectomy
DrugBank Targets:13 1. Low-density lipoprotein receptor;2. High affinity immunoglobulin gamma Fc receptor I
Mechanism of Action:15 
Target: tumor cells
Action: prpagates radical reactions
FDA: Cellular damage caused by photodynamic therapy (PDT) withPHOTOFRIN is a consequence of the propagation of radical reactions.Radical initiation may occur after porfimer sodium absorbs light to forma porphyrin excited state. Spin transfer from porfimer sodium tomolecular oxygen may then generate singlet oxygen. Subsequentradical reactions can form superoxide and hydroxyl radicals. Tumordeath also occurs through ischemic necrosis secondary to vascularocclusion that appears to be partly mediated by thromboxane A2 release.As opposed to a thermal effect, the laser treatment with porfimersodium induces a photochemical effect. The necrotic reaction andassociated inflammatory responses may evolve over several days.
14
Tarceva15 41 ERLOTINIB HYDROCHLORIDE Genentech, OSI Pharmaceuticals November, 2004
FDA Label: Tarceva
Disease/s that Drug Treats:Non-small cell lung cancer
Indications and Usage:15 TARCEVA is a kinase inhibitor indicated for: First-line treatment of patients with metastatic non-small cell lungcancer (NSCLC) whose tumors have epidermal growth factor receptor(EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations asdetected by an FDA-approved test. (1.1) Maintenance treatment of patients with locally advanced or metastaticNSCLC whose disease has not progressed after four cycles of platinumbasedfirst-line chemotherapy. (1.1) Treatment of locally advanced or metastatic NSCLC after failure of atleast one prior chemotherapy regimen. (1.1) First-line treatment of patients with locally advanced, unresectable ormetastatic pancreatic cancer, in combination with gemcitabine. (1.2)
DrugBank Targets:13 1. Epidermal growth factor receptor;2. Nuclear receptor subfamily 1 group I member 2
Mechanism of Action:15 
Target: Human Epidermal Growth Factor Receptor Type 1/Epidermal Growth Factor Receptor (HER1/EGFR) tyrosine kinase
Action: inhibitor
FDA: Epidermal growth factor receptor (EGFR) is expressed on the cell surface of both normal and cancer cells. In some tumor cells signalingthrough this receptor plays a role in tumor cell survival and proliferation irrespective of EGFR mutation status. Erlotinib reversiblyinhibits the kinase activity of EGFR, preventing autophosphorylation of tyrosine residues associated with the receptor and therebyinhibiting further downstream signaling. Erlotinib binding affinity for EGFR exon 19 deletion or exon 21 (L858R) mutations is higherthan its affinity for the wild type receptor. Erlotinib inhibition of other tyrosine kinase receptors has not been fully characterized.
15
Taxol15 41 PACLITAXEL Bristol-Myers Squibb August 1997
FDA Label: Taxol
Disease/s that Drug Treats:Kaposi's Sarcoma
Indications and Usage:15 Paclitaxel Injection, USP is indicated as subsequent therapy for the treatment of advanced carcinoma ofthe ovary. As first-line therapy, Paclitaxel Injection, USP is indicated in combination with cisplatin.Paclitaxel Injection, USP is indicated for the adjuvant treatment of node-positive breast canceradministered sequentially to standard doxorubicin-containing combination chemotherapy.. In the clinicaltrial, there was an overall favorable effect on disease-free and overall survival in the total population ofpatients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen andprogesterone receptor-negative tumors (see CLINICAL STUDIES, Breast Carcinoma).Paclitaxel Injection, USP is indicated for the treatment of breast cancer after failure of combinationchemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapyshould have included an anthracycline unless clinically contraindicated.Paclitaxel Injection, USP, in combination with cisplatin, is indicated for the first-line treatment of nonsmallcell lung cancer in patients who are not candidates for potentially curative surgery and/or radiationtherapy.Paclitaxel Injection, USP is indicated for the second-line treatment of AIDS-related Kaposi’s sarcoma.
DrugBank Targets:13 1. Apoptosis regulator Bcl-2;2. Tubulin beta-1 chain;3. Nuclear receptor subfamily 1 group I member 2;4. Microtubule-associated protein 4;5. Microtubule-associated protein 2;6. Microtubule-associated protein tau
Mechanism of Action:15 
Target: microtubules
Action: promoter of assembly & preventor of depolymerization
FDA: Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulindimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibitionof the normal dynamic reorganization of the microtubule network that is essential for vital interphase andmitotic cellular functions. In addition, paclitaxel induces abnormal arrays or “bundles” of microtubulesthroughout the cell cycle and multiple asters of microtubules during mitosis.Following intravenous administration of paclitaxel, paclitaxel plasma concentrations declined in abiphasic manner. The initial rapid decline represents distribution to the peripheral compartment andelimination of the drug. The later phase is due, in part, to a relatively slow efflux of paclitaxel from theperipheral compartment.Pharmacokinetic parameters of paclitaxel following 3- and 24-hour infusions of paclitaxel at dose levelsof 135 and 175 mg/m2 were determined in a Phase 3 randomized study in ovarian cancer patients and aresummarized in the following table:
16
Taxotere15 41 DOCETAXEL Rhone Poulenc Rorer May 1996
FDA Label: Taxotere
Disease/s that Drug Treats:breast cancer
Indications and Usage:15 TAXOTERE is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BCafter chemotherapy failure; and with doxorubicin andcyclophosphamide as adjuvant treatment of operable node-positive BC(1.1) Non-Small Cell Lung Cancer (NSCLC): single agent for locallyadvanced or metastatic NSCLC after platinum therapy failure; andwith cisplatin for unresectable, locally advanced or metastaticuntreated NSCLC (1.2) Hormone Refractory Prostate Cancer (HRPC): with prednisone inandrogen independent (hormone refractory) metastatic prostate cancer(1.3) Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil foruntreated, advanced GC, including the gastroesophageal junction (1.4) Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN):with cisplatin and fluorouracil for induction treatment of locallyadvanced SCCHN (1.5)
DrugBank Targets:13 1. Tubulin beta-1 chain;2. Apoptosis regulator Bcl-2;3. Microtubule-associated protein 2;4. Microtubule-associated protein 4;5. Microtubule-associated protein tau;6. Nuclear receptor subfamily 1 group I member 2
Mechanism of Action:15 
Target: free tubulin
Action: promoter of assembly
FDA: Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that isessential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes theassembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly. Thisleads to the production of microtubule bundles without normal function and to the stabilization ofmicrotubules, which results in the inhibition of mitosis in cells. Docetaxel’s binding to microtubulesdoes not alter the number of protofilaments in the bound microtubules, a feature which differs from mostspindle poisons currently in clinical use.
17
Xalkori15 41 CRIZOTINIB Pfizer August of 2011
FDA Label: Xalkori
Disease/s that Drug Treats:ALK+ non-small cell lung cancer
Indications and Usage:15 XALKORI is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplasticlymphoma kinase (ALK)-positive as detected by an FDA-approved test. (1)
DrugBank Targets:13 1. ALK tyrosine kinase receptor;2. Hepatocyte growth factor receptor
Mechanism of Action:15 
Target: receptor tyrosine kinases
Action: inhibitor
FDA: Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor(HGFR, c-Met), ROS1 (c-ros), and Recepteur d’Origine Nantais (RON). Translocations can affect the ALKgene resulting in the expression of oncogenic fusion proteins. The formation of ALK fusion proteins results inactivation and dysregulation of the gene’s expression and signaling which can contribute to increased cellproliferation and survival in tumors expressing these proteins. Crizotinib demonstrated concentration-dependentinhibition of ALK, ROS1, and c-Met phosphorylation in cell-based assays using tumor cell lines anddemonstrated antitumor activity in mice bearing tumor xenografts that expressed EML4- or NPM-ALK fusionproteins or c-Met.
18
Xgeva15 41 DENOSUMAB Amgen June 2013/ November 2010
FDA Label: Xgeva
Disease/s that Drug Treats:giant cell tumor of bone/ prevention of skeletal-related events in patients with bone metastases from solid tumors
Indications and Usage:15 Xgeva is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with bone metastasesfrom solid tumors (1.1) Treatment of adults and skeletally mature adolescents with giant celltumor of bone that is unresectable or where surgical resection is likely toresult in severe morbidity (1.2, 14.2) Treatment of hypercalcemia of malignancy refractory to bisphosphonatetherapy (1.3)Limitation of use: Xgeva is not indicated for the prevention of skeletal-relatedevents in patients with multiple myeloma
DrugBank Targets:13 1. Tumor necrosis factor ligand superfamily member 11
Mechanism of Action:15 
Target: RANKL
Action: modulator of calcium release
FDA: Xgeva binds to RANKL, a transmembrane or soluble protein essential for the formation, function, andsurvival of osteoclasts, the cells responsible for bone resorption, thereby modulating calcium release frombone. Increased osteoclast activity, stimulated by RANKL, is a mediator of bone pathology in solidtumors with osseous metastases. Similarly, giant cell tumors of bone consist of stromal cells expressingRANKL and osteoclast-like giant cells expressing RANK receptor, and signaling through the RANKreceptor contributes to osteolysis and tumor growth. Xgeva prevents RANKL from activating itsreceptor, RANK, on the surface of osteoclasts, their precursors, and osteoclast-like giant cells.
19
Zometa15 41 ZOLEDRONIC ACID Novartis August 2001/ February 2002
FDA Label: Zometa
Disease/s that Drug Treats:Hypercalcemia of malignancy/ Multiple myeloma; bone metastases from solid tumors
Indications and Usage:15 Zometa is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy. (1.1) Patients with multiple myeloma and patients with documented bonemetastases from solid tumors, in conjunction with standard antineoplastictherapy. Prostate cancer should have progressed after treatment with atleast one hormonal therapy. (1.2)Important limitation of use: The safety and efficacy of Zometa has not beenestablished for use in hyperparathyroidism or nontumor-relatedhypercalcemia. (1.3)
DrugBank Targets:13 1. Farnesyl pyrophosphate synthase;2. Geranylgeranyl pyrophosphate synthase;3. Hydroxylapatite
Mechanism of Action:15 
Target: bone resorption
Action: inhibitor
FDA: The principal pharmacologic action of zoledronic acid is inhibition of bone resorption. Although theantiresorptive mechanism is not completely understood, several factors are thought to contribute to this action.In vitro, zoledronic acid inhibits osteoclastic activity and induces osteoclast apoptosis. Zoledronic acid alsoblocks the osteoclastic resorption of mineralized bone and cartilage through its binding to bone. Zoledronic acidinhibits the increased osteoclastic activity and skeletal calcium release induced by various stimulatory factorsreleased by tumors.
20
Zykadia15 41 CERITINIB Novartis April 2014
FDA Label: Zykadia
Disease/s that Drug Treats:ALK+ metastatic non-small cell lung cancer
Indications and Usage:15 ZYKADIA is a kinase inhibitor indicated for the treatment of patients withanaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lungcancer (NSCLC) who have progressed on or are intolerant to crizotinib. Thisindication is approved under accelerated approval based on tumor responserate and duration of response. An improvement in survival or disease-relatedsymptoms has not been established. Continued approval for this indicationmay be contingent upon verification and description of clinical benefit inconfirmatory trials. (1)
DrugBank Targets:13 1. ALK tyrosine kinase receptor
Mechanism of Action:15 
Target: ALK, insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1
Action: kinase inhibitor
FDA: Ceritinib is a kinase inhibitor. Targets of ceritinib inhibition identified in either biochemical or cellular assays at clinicallyrelevant concentrations include ALK, insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1.Among these, ceritinib is most active against ALK. Ceritinib inhibited autophosphorylation of ALK, ALK-mediatedphosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells in in vitroand in vivo assays.Ceritinib inhibited the in vitro proliferation of cell lines expressing EML4-ALK and NPM-ALK fusion proteins anddemonstrated dose-dependent inhibition of EML4-ALK-positive NSCLC xenograft growth in mice and rats. Ceritinibexhibited dose-dependent anti-tumor activity in mice bearing EML4-ALK-positive NSCLC xenografts with demonstratedresistance to crizotinib, at concentrations within a clinically relevant range.
21
Abraxane15 PACLITAXEL Celgene October 2012
FDA Label: Abraxane
Disease/s that Drug Treats:non-small cell lung cancer
Indications and Usage:15 ABRAXANE is a microtubule inhibitor indicated for the treatment of: * Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. (1.1) * Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. (1.2) * Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine. (1.3)
DrugBank Targets:13 Apoptosis regulator Bcl-2|Tubulin beta-1 chain|Nuclear receptor subfamily 1 group I member 2|Microtubule-associated protein 4|Microtubule-associated protein 2|Microtubule-associated protein tau|
Mechanism of Action:15 
Target: microtubule
Action: inhibitor
FDA: ABRAXANE is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. Paclitaxel induces abnormal arrays or “bundles” of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.
22
Alecensa15 ALECTINIB HYDROCHLORIDE Roche December 2015
FDA Label: Alecensa
Disease/s that Drug Treats:ALK-positive, metastatic non-small cell lung cancer
Indications and Usage:15 ALECENSA is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. (1)
DrugBank Targets:13 ALK tyrosine kinase receptor
Mechanism of Action:15 
Target: ALK and RET
Action: kinase inhibitor
FDA: Alectinib is a tyrosine kinase inhibitor that targets ALK and RET. In nonclinical studies, alectinib inhibited ALK phosphorylation and ALK-mediated activation of the downstream signaling proteins STAT3 and AKT, and decreased tumor cell viability in multiple cell lines harboring ALK fusions, amplifications, or activating mutations. The major active metabolite of alectinib, M4, showed similar in vitro potency and activity. Alectinib and M4 demonstrated in vitro and in vivo activity against multiple mutant forms of the ALK enzyme, including some mutations identified in NSCLC tumors in patients who have progressed on crizotinib. In mouse models implanted with tumors carrying ALK fusions, administration of alectinib resulted in antitumor activity and prolonged survival, including in mouse models implanted intracranially with ALK-driven tumor cell lines.
23
Iressa15 GEFITINIB AstraZeneca May 2003
FDA Label: Iressa
Disease/s that Drug Treats:Non-Small-Cell Lung Cancer
Indications and Usage:15 IRESSA is indicated as monotherapy for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies who are benefiting or have benefited from IRESSA. In light of positive survival data with other agents including another oral EGFR inhibitor, physicians should use other treatment options in advanced non-small cell lung cancer patient populations who have received one or two prior chemotherapy regimens and are refractory or intolerant to their most recent regimen. The effectiveness of IRESSA was initially based on objective response rates (see CLINICAL PHARMACOLOGY-Clinical Studies section). Subsequent studies intended to demonstrate an increase in survival have been unsuccessful. Specifically, results from a large placebo-controlled randomized trial in patients with advanced NSCLC who progressed while receiving or within 90 days of the last dose of chemotherapy or were intolerant to the most recent prior chemotherapy regimen, did not show an improvement in survival (see CLINICAL PHARMACOLOGY- Clinical Studies section). Results from two large, controlled, randomized trials in first-line treatment of non-small cell lung cancer showed no benefit from adding IRESSA to doublet, platinum-based chemotherapy.
DrugBank Targets:13 Epidermal growth factor receptor
Mechanism of Action:15 
Target: EGFR tyrosine kinase
Action: inhibitor
FDA: The mechanism of the clinical antitumor action of gefitinib is not fully characterized. Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells. No clinical studies have been performed that demonstrate a correlation between EGFR receptor expression and response to gefitinib.
24
Opdivo15 NIVOLUMAB Bristol-Myers Squibb March 2015
FDA Label: Opdivo
Disease/s that Drug Treats:metastatic squamous non-small cell lung cancer
Indications and Usage:15 OPDIVO is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with: * unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. (1.1) This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. (1.1, 14.1) * metastatic squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy. (1.2)
DrugBank Targets:13 Programmed cell death protein 1
Mechanism of Action:15 
Target: PD-1 receptor
Action: blocks its interaction with PD-L1 and PD-L2
FDA: Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.
25
Portazza15 NECITUMUMAB Eli Lilly November 2015
FDA Label: Portazza
Disease/s that Drug Treats:metastatic squamous non-small cell lung cancer
Indications and Usage:15 PORTRAZZA™ is an epidermal growth factor receptor (EGFR) antagonist indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer. (1.1) Limitation of Use: PORTRAZZA is not indicated for treatment of non-squamous non-small cell lung cancer. (1.2, 5.6, 14.2)
DrugBank Targets: -
Mechanism of Action:15 
Target: EGFR
Action: blocks the binding of EGFR to its ligands
FDA: Necitumumab is a recombinant human lgG1 monoclonal antibody that binds to the human epidermal growth factor receptor (EGFR) and blocks the binding of EGFR to its ligands. Expression and activation of EGFR has been correlated with malignant progression, induction of angiogenesis, and inhibition of apoptosis. Binding of necitumumab induces EGFR internalization and degradation in vitro. In vitro, binding of necitumumab also led to antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. In in vivo studies using xenograft models of human cancer, including non-small cell lung carcinoma, administration of necitumumab to implanted mice resulted in increased antitumor activity in combination with gemcitabine and cisplatin as compared to mice receiving gemcitabine and cisplatin alone.
26
Tagrisso15 OSIMERTINIB MESYLATE AstraZeneca November 2015
FDA Label: Tagrisso
Disease/s that Drug Treats:EGFR T790M mutation positive non-small cell lung cancer
Indications and Usage:15 TAGRISSO is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutationpositive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, who have progressed on or after EGFR TKI therapy. (1) This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. (1)
DrugBank Targets: -
Mechanism of Action:15 
Target: epidermal growth factor receptor (EGFR)
Action: kinase inhibitor
FDA: Osimertinib is kinase inhibitor of the epidermal growth factor receptor (EGFR), which binds irreversibly to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletion) at approximately 9-fold lower concentrations than wild-type. In cultured cells and animal tumor implantation models, osimertinib exhibited anti-tumor activity against NSCLC lines harboring EGFR-mutations (T790M/L858R, L858R, T790M/exon 19 deletion, and exon 19 deletion) and, to a lesser extent, wild-type EGFR amplifications. Two pharmacologically-active metabolites (AZ7550 and AZ5104 circulating at approximately 10% of the parent) with similar inhibitory profiles to osimertinib have been identified in the plasma after oral administration of osimertinib. AZ7550 showed a similar potency to osimertinib, while AZ5104 showed greater potency against exon 19 deletion and T790M mutants (approximately 8-fold) and wild-type (approximately 15-fold) EGFR. In vitro, osimertinib also inhibited the activity of HER2, HER3, HER4, ACK1, and BLK at clinically relevant concentrations.
27
Xalkori15 CRIZOTINIB Pfizer August of 2011
FDA Label: Xalkori
Disease/s that Drug Treats:ALK+ non-small cell lung cancer
Indications and Usage:15 XALKORI is a kinase inhibitor indicated for the treatment of patients with: * metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (1.1) * metastatic NSCLC whose tumors are ROS1-positive. (1.2)
DrugBank Targets:13 ALK tyrosine kinase receptor|Hepatocyte growth factor receptor
Mechanism of Action:15 
Target: receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and Recepteur d’Origine Nantais (RON)
Action: inhibitor
FDA: Crizotinib is an inhibitor of receptor tyrosine kinases including ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), ROS1 (c-ros), and Recepteur d’Origine Nantais (RON). Translocations can affect the ALK gene resulting in the expression of oncogenic fusion proteins. The formation of ALK fusion proteins results in activation and dysregulation of the gene’s expression and signaling which can contribute to increased cell proliferation and survival in tumors expressing these proteins. Crizotinib demonstrated concentration-dependent inhibition of ALK, ROS1, and c-Met phosphorylation in cell-based assays using tumor cell lines and demonstrated antitumor activity in mice bearing tumor xenografts that expressed echinoderm microtubule-associated protein-like 4 (EML4)- or nucleophosmin (NPM)-ALK fusion proteins or c-Met.
28
Zykadia15 CERITINIB Novartis April 2014
FDA Label: Zykadia
Disease/s that Drug Treats:ALK+ metastatic non-small cell lung cancer
Indications and Usage:15 ZYKADIA is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. (1)
DrugBank Targets:13 ALK tyrosine kinase receptor
Mechanism of Action:15 
Target: anaplastic lymphoma kinase (ALK)
Action: highly-selective inhibitor
FDA: Ceritinib is a kinase inhibitor. Targets of ceritinib inhibition identified in either biochemical or cellular assays at clinically relevant concentrations include ALK, insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1. Among these, ceritinib is most active against ALK. Ceritinib inhibited autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells in in vitro and in vivo assays. Ceritinib inhibited the in vitro proliferation of cell lines expressing EML4-ALK and NPM-ALK fusion proteins and demonstrated dose-dependent inhibition of EML4-ALK-positive NSCLC xenograft growth in mice and rats. Ceritinib exhibited dose-dependent anti-tumor activity in mice bearing EML4-ALK-positive NSCLC xenografts with demonstrated resistance to crizotinib, at concentrations within a clinically relevant range.

Drugs for Lung Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 820)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
AcetaminophenapprovedPhase 4, Phase 2, Phase 1864103-90-21983
Synonyms:
4'-Hydroxyacetanilide
4'-hydroxyacetanilide
4-(Acetylamino)phenol
4-Acetamidophenol
4-Acetaminophenol
4-Hydroxyacetanilide
4-Hydroxyanilid kyseliny octove
4-acetamidophenol
7 Select Acetaminophen
7 Select Childrens Pain Relief
8 Hour Pain Relief
A-Per
A.F. Anacin
AC1Q1KYJ
AC1Q1KYK
APAP
Abenol
Abensanil
Abrol
Abrolet
Acamol
Accu-Tap
Acenol
Acephen
Acertol
Aceta Elixir
Aceta Tablets
Acetaco
Acetagesic
Acetalgin
Acetaminofen
Acetaminophen
Acetaminophen (red)
Acetaminophen - Apap 8 Hour
Acetaminophen - Apap Arthritis
Acetaminophen 8 Hour
Acetaminophen 8 hour
Acetaminophen EXTRA STRENGTH
Acetaminophen Easy Tabs Extra Strength
Acetaminophen Extended Release
Acetaminophen Extra Strength
Acetaminophen Junior
Acetaminophen Maximum Strength
Acetaminophen PAIN RELIEF
Acetaminophen Rapid Release
Acetaminophen Rapid Release Extra Strength
Acetaminophen Regular Strength
Acetaminophen Uniserts
Acetaminophen arthritis pain
Acetaminophen easy tabs
Acetaminophen extra strength
Acetaminophen for children
Acetaminophen infants
Acetaminophen pain reliever fever reducer
Acetaminophen pain reliever/fever reducer
Acetaminophen-apap 8 Hour
Acetaminophene
Acetamol
Acetavance
Acetofen
Actamin
Actamin Extra
Actamin Super
Actifed Plus
Actimol
Actimol Chewable Tablets
Actimol Children'S Suspension
Actimol Infants' Suspension
Actimol Junior Strength Caplets
Actron
Afebrin
Afebryl
Aferadol
Algesidal
Algina
Algomol
Algotropyl
Allay
Alpiny
Alpinyl
Alvedon
Amadil
Aminofen
Aminofen Max
Anacin
Anacin 3
Anacin Aspirin Free
Anacin-3
Anacin-3 Extra Strength
Anadin dla dzieci
Anaflon
Analter
Anapap
Andox
Anelix
Anexsia
Anexsia 10/660
Anexsia 5/325
Anexsia 7.5/325
Anexsia 7.5/650
Anhiba
Anoquan
Anti-Algos
Antidol
Anuphen
Apacet
Apacet Capsules
Apacet Elixir
Apacet Extra Strength Caplets
Apacet Extra Strength Tablets
Apacet Regular Strength Tablets
Apadon
Apamid
Apamide
Apap
Apap Extra Strength
Apap extra strength
Aphen
Apinophen EXTRA STRENGTH
Apitrelal
Apo-Acetaminophen
Arfen
Arthralgen
Arthritis 8 Hour
Arthritis Pain
Arthritis Pain Relief
Arthritis Pain Relief temporary minor
Arthritis Pain Reliever
Asetam
Asomal
Aspac
Aspirin Free
Aspirin Free Anacin Maximum Strength Caplets
Aspirin Free Anacin Maximum Strength Gel Caplets
Aspirin Free Anacin Maximum Strength Tablets
Aspirin Free Pain Relief
Aspirin-Free Anacin
Aspirin-Free Excedrin Caplets
Asplin
Atasol
Atasol Caplets
Atasol Drops
Atasol Forte Caplets
Atasol Forte Tablets
Atasol Oral Solution
Atasol Tablets
Atralidon
Aypanal
Babies R Us Childrens Pain Relief
Babies R Us Infants Pain Relief
Babies R Us Pain Relief
Babikan
Bacetamol
Bancap
Bancap Hc
Banesin
Bayer Select
Bayer Select Allergy-Sinus
Bayer Select Head Cold
Bayer Select Headache Pain
Bayer Select Maximum Strength Headache Pain Relief Formula
Bayer Select Menstrual Multi-Symptom
Bayer Select Sinus Pain Relief
Ben-u-ron
Benmyo
Bf-paradac
Bickie-mol
Biocetamol
Bucet
Butalbital
Butapap
CCRIS 3
CHEBI:46195
Cadafen
Calapol
Calmanticold
Calonal
Calpol
Capital
Capital with Codeine
Captin
Care One Arthritis Pain Relief
Care One Arthritis Pain Relief temporary minor
Care One Pain Relief
Care One Pain Relief 8 hour
Care One Pain Relief Childrens
Care One Pain Relief childrens
Care One Pain Relief extra strength
Care One Pain Relief infants
Careone Infants Pain Relief
Careone Pain Relief
Careone Pain Relief infants
Causalon
Cefalex
Cetadol
Cetafen
Cetafen Extra
Children Acetaminophen Grape Flavored Chewable
Children'S Acetaminophen Elixir Drops
Children'S Acetaminophen Oral Solution
Children'S Tylenol Chewable
Children's Pain Relief
Childrens Accudial Pain reliever/ Fever reducer
Childrens Acetaminophen
Childrens Acetaminophen Melts
Childrens Acetaminophen Oral Suspension Grape Flavor
Childrens Aspirin Free Rapid Tabs
Childrens Chewable Acetaminophen
Childrens Chewable Mapap
Childrens Chewable Pain Reliever
Childrens Fever Reducer
Childrens Mapap
Childrens Mapap Acetaminophen
Childrens Non Aspirin
Childrens Nortemp
Childrens Pain Relief
Childrens Pain Relief Acetaminophen
Childrens Pain Relief Bubblegum
Childrens Pain Relief Grape Flavor
Childrens Pain Relief ReadyInCase
Childrens Pain Reliever
Childrens Qpap
Childrens Silapap
Childrens Tylenol
Childrens non aspirin
Circle K Pain Reliever
Claradol Codeine
Clixodyne
Co-Gesic
Cod-Acamol Forte
Codabrol
Codalgin
Codapane
Codicet
Codisal
Codisal Forte
Codoliprane
Codral Pain Relief
Cofamol
Conacetol
Concentrated Aspirin Free infants
Conrx Extra Strength
Contac Cough & Sore Throat Formula
Contra-Schmerz P
Coricidin
Coricidin D
Coricidin Sinus
Cosutone
Counteract Childrens Pain Reliever
Counteract Pain
Croix Blanche
Cuponol
Curadon
Curpol
Custodial
D oliprane
Dafalgan
Dapa
Dapa X-S
Darocet
Darvocet
Darvocet-N 50
Datril
Datril Extra-Strength
Daygrip
Demilets
Deminofen
Democyl
Demogripal
Desfebre
Dg Health Arthritis Pain Relief
Dg Health Childrens Pain Relief
Dg Health Pain Relief
Dg Health Pain Relief Infants
Dg Health Pain Relief childrens
Dg Health Pain Reliever
Dg Health Pain Reliever extra strength
Dhamol
Dhc Plus
Dial-a-gesic
Dial-alpha-gesic
Dimindol
Direct Safety Aspirin Free
Direct Safety Extra Strength Aspirin Free
Dirox
Disprol
Dol-Stop
Dolcor
Dolefin
Dolegrippin
Dolene AP-65
Dolene Ap-65
Dolgesic
Doliprane
Dolko
Dolofin Infantil
Dolofugin
Doloreduct
Dolorfug
Dolorol Forte
Dolorstop
Dolotec
Dolprone
Dorocoff
Dover Aminophen
Dresan
Dristan Cold No Drowsiness
Dristancito
Drixoral Plus
Duaneo
Dularin
Duorol
Duracetamol
Duradyne Dhc
Durapan
Dye-free Childrens Acetaminophen Grape
Dymadon
Dymadon Co
Dymadon Forte
Dypap
Ecosetol
Ed Apap
Elixodyne
Empracet
Endecon
Enelfa
Eneril
Equaline Acetaminophen infants
Equaline Arthritis
Equaline Childrens Acetaminophen
Equaline Infants Acetaminophen
Equaline Pain Relief
Equaline Pain Relief childrens
Equaline Pain Relief concentrated
Equaline Pain Relief extra strength
Equaline Pain Relief infants
Equaline Pain Relief infants concentrated
Equate Acetaminophen
Equate Arthritis Pain
Equate Childrens Acetaminophen
Equate Pain Reliever Extra Strength
Esgic
Esgic-Plus
Eu-Med
Excedrin
Excedrin Caplets
Excedrin Extra Strength Caplets
Excipain
Exdol
Exdol Strong
Extra Strength Acetaminohpen Adult Rapid Burst Cherry
Extra Strength Acetaminophen
Extra Strength Aspirin Free Pain Relief
Extra Strength Headache Relief
Extra Strength Mapap
Extra Strength Non-aspirin
Extra Strength Non-aspirin Pain Reliever
Extra Strength Pain Relief
Extra Strength Pain Relief Acetaminophen
Extra Strength Pain Reliever
Extra Strength Qpap
Extra Strength Wal-nadol
Family Wellness Acetaminophen
Fanalgic
Farmadol
Febranine
Febrectal
Febrectol
Febrex
Febricet
Febridol
Febrilix
Febrin
Febrinol
Febro-Gesic
Febrolin
Femcet
Fendon
Fensum
Fepanil
Fever All
Fever Reducing childrens
Feverall
Feverall Adults
Feverall Children
Feverall Childrens
Feverall Infants
Feverall Jr. Strength
Feverall Junior
Feverall Junior Strength
Feverall Sprinkle Caps Junior Strength
Fevor
Finimal
Finiweh
Fioricet
Fluparmol
Formu Care Pain Relief
Fortalidon P
Fortolin
Freka-cetamol
Fulton Street Market Pain Relief extra strength
Gattaphen T
Gelocatil
Geluprane
Genapap
Genapap Children'S Elixir
Genapap Children'S Tablets
Genapap Extra Strength Caplets
Genapap Extra Strength Tablets
Genapap Regular Strength Tablets
Genebs
Genebs Extra Strength Caplets
Genebs Regular Strength Tablets
Genebs X-Tra
Geralgine-P
Gesteira
Good Neighbor Pharmacy 8 Hour Pain Relief
Good Neighbor Pharmacy Childrens Pain Relief
Good Neighbor Pharmacy Pain Relief
Good Neighbor Pharmacy Pain Relief Infants
Good Neighbor Pharmacy Pain Relief Rapid Release Extra Strength
Good Neighbor Pharmacy Pain Relief childrens
Good Neighbor Pharmacy Pain Relief extra strength
Good Neighbor Pharmacy Pain Relief infants
Good Neighbor Pharmacy Pain Relief regular strength
Good Sense Pain Relief
Good Sense Pain Relief 8 hour
Good Sense Pain Relief Extra Strength
Good Sense Pain Relief arthritis pain
Good Sense Pain Relief childrens
Good Sense Pain Relief extra strength
Good Sense Pain Relief infants concentrated
Good Sense Pain Reliefchildrens childrens
Green Guard Maximum Non-aspirin
Gripin Bebe
Grippostad
Gynospasmine
Health Mart Junior Rapid Melts
Health Mart Pain Relief
Health Sense Tactinal Extra Strength
Health Sense Tactinal Regular Strength
Healthy Accents Arthritis Pain Relief
Healthy Accents Pain Relief
Healthy Accents Pain Relief childrens
Healthy Accents Pain Relief extra strength
Healthy Accents Pain Relief infants
Healthy Mama SHAKE THAT ACHE
Hedex
Helon N
Help I Have A Headache
Henry Schein Acetaminophen
Homoolan
Hy-Phen
Hycomine Compound
Hydrocet
Ildamol
Inalgex
Infadrops
Infants Acetaminophen
Infants Acetaminophen Concentrated
Infants Mapap
Infants Mapap Pain Reliever /Fever Reducer
Infants Pain Relief
Infants Pain Relief Concentrated
Infants Pain Relief concentrated
Infants Pain Reliever
Infants Silapap
Infants Tylenol
Infants concentrated aspirin free
Infants' Feverall
Influbene N
Injectapap
Intensin
Janupap
Jin Gang
Junior Acetaminophen
Junior Aspirin Free Rapid Tabs
Junior Disprol
Junior Pain Relief
Junior Rapid Melts Grape
Junior Strength Acetaminophen
Junior Strength Pain Relief
Junior Strength Pain Reliever
Junior Strength Pain Reliever Grape
KBio1_000660
Kataprin
Kinder Finimal
Kirkland Signature Acetaminophen adult extra strength
Kirkland Signature Arthritis Pain
Kirkland Signature Infants Pain Relief
Kirkland Signature Non Aspirin Extra Strength
Kirkland Signature Pain Relief
Korum
Kratofin simplex
L024125
Labamol
Leader 8 Hour Pain Reliever
Leader Arthritis Pain
Leader Arthritis Pain Reliever
Leader Childrens Pain Reliever
Leader Extra Strength Pain Relief
Leader Pain Relief 8 HR
Leader Pain Relief childrens
Leader Pain Reliever
Leader Pain Reliever childrens
Leader Pain Reliever extra strength
Leader Pain Reliever infants
Leader Pain Reliever infants concentrated
Lekadol
Lemgrip
Lemsip
Lestemp
 
Lil Drug Store Pain Reliever Extra Strength
Liqiprine
Liquagesic
Liquigesic Co
Liquiprin
Liquiprin Children'S Elixir
Liquiprin Infants" Drops
Little Fevers By Little Remedies
Little Fevers Childrens Fever Pain Reliever
Little Fevers Infant Berry Fever/pain Reliever
Little Fevers Infant Grape Fever/pain Reliever
Lonarid
Lonarid Mono
Lorcet-Hd
Lortab
Lupocet
Lyteca
Lyteca Syrup
Magnidol
Malex N
Malgis
Malidens
Mapap
Mapap Arthritis Pain
Mapap Extra Strength
Mapap childrens
Mapap infants concentrated
Maxadol
Medi First Plus Non-aspirin
Medi First Plus Non-aspirin Extra Strength
Medi-first Non-aspirin
Medi-first Non-aspirin Extra Strength
Medicine Shoppe Arthritis Pain Reliever
Medigesic Plus
Medinol Paediatric
Medique Apap
Medique Apap Extra Strength
Medline Acetaminophen
Medocodene
Melabon Infantil
Members Mark Acetaminophen
Members Mark Arthritis Pain
Mexalen
Midol Maximum Strength
Midol PM Night Time Formula
Midol Regular Strength
Midol Teen Formula
Migraleve Yellow
Minafen
Minoset
Miralgin
Momentum
Mono Praecimed
Moore Medical Extra Strength Non Aspirin
Moore Medical Non Aspirin
Multin
N-(4-Hydroxyphenyl)acetamide
N-Acetyl-4-aminophenol
N-Acetyl-p-aminophenol
N-acetyl-p-aminophenol
NAPA
NCX 701
NEBS
NSC3991
Naldegesic
Napafen
Napap
Naprinol
Nealgyl
Nebs
Neo-Fepramol
NeoCitran
Neodol
Neodolito
Neopap
Neotrend
Neuridon
New Cortal for Children
NilnOcen
Nina
No-Febril
Nobedon
Nodolex
Non Aspirin Childrens
Non Aspirin Extra Strength
Non-aspirin
Noral
Norcet
Norco
Nortemp
O-Acetaminophenol
Ofirmev
Ohm 8 Hour Pain Reliever/fever Reducer
Oltyl
Oralgan
Oraphen-PD
Ortensan
Oxycet
Oxycocet
Oxycodone 2.5/Apap 500
Oxycodone 5/Apap 500
PCM Paracetamol Lichtenstein
Paceco
Pacemo
Pacemol
Pacet
Pacimol
Paedialgon
Paedol
Pain Relief
Pain Relief 8 Hr
Pain Relief 8 hour
Pain Relief Acetaminophen Extra Strength
Pain Relief Childrens
Pain Relief ES
Pain Relief Extra Strength
Pain Relief Infants
Pain Relief Regular Strength
Pain Relief childrens
Pain Relief concentrated infants
Pain Relief extra strength
Pain Relief infants
Pain Relief regular strength
Pain Reliever
Pain Reliever Extra Strength
Pain Reliever Extra Strength (Leader)
Pain Reliever Fever Reducer childrens
Pain Reliever Infants
Pain Reliever Rapid Release
Pain Reliever childrens
Pain Reliever extra strength
Pain Reliever infants
Painex
Paldesic
Pamol
Panacete
Panadeine
Panadeine Co
Panadiene
Panado-Co
Panado-Co Caplets
Panadol
Panadol Extra Strength
Panadol Junior Strength Caplets
Panadol Maximum Strength Caplets
Panadol Maximum Strength Tablets
Panale ve
Panaleve
Panamax
Panasorb
Panasorbe
Panets
Panex
Panodil
Panofen
Pantalgin
Papa-Deine
Papa-Deine #3
Papa-Deine #4
Para-Suppo
Para-Tabs
Paracemol
Paracenol
Paracet
Paracetamol
Paracetamol AL
Paracetamol Antipanin P
Paracetamol BC
Paracetamol Basics
Paracetamol DC
Paracetamol Dr. Schmidgall
Paracetamol Fecofar
Paracetamol Genericon
Paracetamol Hanseler
Paracetamol Harkley
Paracetamol Heumann
Paracetamol Hexal
Paracetamol Italfarmaco
Paracetamol Nycomed
Paracetamol PB
Paracetamol Raffo
Paracetamol Ratiopharm
Paracetamol Rosch
Paracetamol Saar
Paracetamol SmithKline Beecham
Paracetamol Stada
Paracetamol Winthrop
Paracetamol von ct
Paracetamole
Paracetamolo
Paracetamolum
Paracetanol
Paracetol
Paracin
Paracod
Paracodol
Parador
Paradrops
Parakapton
Parake
Paralen
Paralief
Paralink
Paralyoc
Paramol
Paramolan
Paranox
Parapan
Parasedol
Parasin
Paraspen
Parcetol
Parelan
Parmol
Parogal
Paroma
Pasolind
Pasolind N
Pe-Tam
Pediacare Childrens Fever Reducer Pain Reliever Cherry
Pediacare Childrens Fever Reducer Pain Reliever Dye Free
Pediacare Childrens Fever Reducer Pain Reliever Grape
Pediacare Infant Fever Pain Reliever
Pediacare Infants Fever Reducer Cherry
Pediacare Infants Fever Reducer Dye Free
Pediacare Infants Fever Reducer Grape
Pediacare Single Dose Fever Reducer
Pediapirin
Pediatrix
Pedric
Percocet
Percocet-5
Percocet-Demi
Percogesic with Codeine
Perdolan Mono
Perfalgan
Pharbetol
Pharbetol Regular strength
Phenaphen
Phenaphen Caplets
Phenaphen W/Codeine
Phendon
Phenipirin
Phogoglandin
Phrenilin
Phrenilin Forte
Physicianscare Non Aspirin Extra Strength
Pinex
Piramin
Pirinasol
Plicet
Plus Pharma Pain Reliever,Fever Reducer 325 mg
Pluspharma Extra Strength PAIN RELIEVER,FEVER REDUCER 500 mg
Polmofen
Powerful Pain Medicine
Predimol
Predualito
Preferred Plus Arthritis Pain
Preferred Plus Extra Strength Pain Relief
Premier Value Arthritis 8 Hour
Premier Value Arthritis Pain Reliever
Prestwick_13
Prodol
Prompt
Prontina
Propacet
Propacet 100
Proval #3
Puernol
Pulmofen
Pyregesic-C
Pyrigesic
Pyrinazine
Pyromed
Qpap Infants Drops
Quality Choice Extra Strength Pain Relief
Quiet World
Rapid Comfort Extra Strength Non Aspirin
Rapid Comfort Non Aspirin
Rapid Release Acetaminophen
Redutemp
Regular Strength Pain Relief
Regular Strength Pain Reliever
Regular Strength Qpap
Reliv
Remedol
Rexall Arthritis Pain
Rexall Pain Relief
Rhinex D-Lay Tablets
Ringl
Rivalgyl
Robigesic
Robitussin Night Relief
Rockamol Plus
Rounox
Roxicet
Roxicet 5/500
Roxilox
RubieMol
Rubophen
Rugby Acetaminophen
Rupemol
Rx Act Pain Relief
Rx Act Pain Relief 8 Hr
Rx Act Pain Relief Extra Strength
Rx Act Pain Relief Rapid Release
Rx Act Pain Relief extra strength
Rx Act Pain Relief infants
Rx Act Pain Relief regular strength
SK-Apap
SPBio_002836
Salzone
Sanicet
Sanicopyrine
Scanol
Scentalgyl
Scherzatabletten Rezeptur 534
Schmerzex
Sedalito
Sedapap
Semolacin
Servigesic
Seskamol
Setakop
Setamol
Setol
Severe Sinus Congestion
Shoprite Acetaminophen
Shoprite Arthritis Pain
Shoprite Childrens Acetaminophen
Shoprite Infants Acetaminophen
Shoprite Pain Relief
Sifenol
Simply Right Acetaminophen
Simply Right Arthritis Pain
Sinaspril
Sine-Off Sinus Medicine Caplets
Sinedol
Sinmol
Sinubid
Smart Sense Arthritis Pain Relief
Smart Sense Childrens Pain Relief
Smart Sense Infants Pain Relief
Smart Sense Pain Relief
Smart Sense Pain Relief 8 hour
Smart Sense Pain Relief Extra Strength
Smart Sense Pain Relief childrens
Smart Sense Pain Relief extra strength
Smart Sense Pain Relief infants
Snaplets-FR
Sohmed Extra Strength
Spalt N
Spalt fur die nacht
St Joseph Aspirin-Free
St Joseph Aspirin-Free for Children
St. Joseph Cold Tablets for Children
St. Joseph Fever Reducer
Stanback
Stopain
Sudafed Severe Cold Formula
Sudafed Sinus
Sunetheton
Sunmark 8 Hour Pain Relief
Sunmark Arthritis 8 Hour
Sunmark Arthritis Pain Relief
Sunmark Arthritis Pain Reliever
Sunmark Junior Rapid Melts
Sunmark Pain Relief Extra Strength
Sunmark Pain Reliever
Sunmark Pain Reliever Infants
Sunmark Pain Reliever extra strength
Sunmark Pain Reliever infants
Supac
Supadol mono
Supofen
Suppap
Suppap-120
Suppap-325
Suppap-650
Supramol-M
Swift Aypanal Extra
Synalgos-Dc-A
TYL
Tabalgin
Tachiprina
Talacen
Tapanol
Tapanol Extra Strength Caplets
Tapanol Extra Strength Tablets
Tapar
Tavist Allergy/Sinus/Headache
Tazamol
Temlo
Tempanal
Tempra
Tempra Caplets
Tempra Chewable Tablets
Tempra D.S
Tempra Drops
Tempra Syrup
Tencon
Termacet
Termalgin
Termalgine
Termofren
TheraFlu
Tibinide
Tibizide
Tiffy
Tisin
Tisiodrazida
Titralgan
Tizide
Tocris-1706
Topcare 8 Hour Pain Relief
Topcare Arthritis Pain
Topcare Arthritis Pain Relief
Topcare Arthritis Pain Relief Temporary Minor
Topcare Childrens Pain Relief
Topcare Fever Reducer
Topcare Infants Pain Relief
Topcare Pain Relief
Topcare Pain Relief Extra Strength
Topcare Pain Relief Infants
Topcare Pain Relief Rapid Release
Topcare Pain Relief extra strength
Topcare Pain Relief extra strength easy to swallow
Topco Arthritis 8 Hour
Toximer P
Tralgon
Treupel N
Treupel mon
Treuphadol
Triad
Triaminic Fever Reducer
Triaminic Infants Fever Reducer Pain Reliever - Bubblegum
Triaminic Infants Fever Reducer Pain Reliever - Grape
Triaminic Sore Throat Formula
Triaprin
Tricoton
Tussapap
Ty lenol
Tycolet
Tylenol
Tylenol (TN)
Tylenol Allergy Sinus
Tylenol Arthritis Extended Relief
Tylenol Arthritis Pain
Tylenol Caplets
Tylenol Children'S Chewable Tablets
Tylenol Children'S Elixir
Tylenol Children'S Suspension Liquid
Tylenol Cold Sore Throat Extra Strength
Tylenol Drops
Tylenol Elixir
Tylenol Extra Strength
Tylenol Extra Strength Adult Liquid Pain Reliever
Tylenol Extra Strength Caplets
Tylenol Extra Strength Gelcaps
Tylenol Extra Strength Tablets
Tylenol Gelcaps
Tylenol Infants Drops
Tylenol Infants" Suspension Drops
Tylenol Junior Strength Caplets
Tylenol Junior Strength Chewable Tablets
Tylenol Regular Strength
Tylenol Regular Strength Caplets
Tylenol Regular Strength Tablets
Tylenol SORE THROAT
Tylenol Tablets
Tylex
Tylex CD
Tylo Extra Strength
Tylol
Tylox
Tylox-325
Tymol
Ultracet
Upsanol
Utragin
Valadol
Valgesic
Valorin
Valorin Extra
Vanquish
Veralgina
Vermidon
Verpol
Viclor Richet
Vicodin
Vicodin Es
Vicodin Hp
Vips
Viruflu
Vivimed
Volpan
Welby Health Acetaminophen
Wygesic
Xl-dol
Zatinol
Zee Unaspirin ES
Zolben
alpha-Per
p-(Acetylamino)phenol
p-Acetamidophenol
p-Acetaminophenol
p-Acetylaminophenol
p-Hydroxyacetanilide
p-Hydroxyphenolacetamide
p-acetamidophenol
p-acetaminophenol
p-hydroxyacetanilide
p-hydroxyphenolacetamide
2
Miconazoleapproved, investigationalPhase 4, Phase 2, Phase 1, Phase 0302622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
Desenex
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Makesense
Micantin (nitrate)
Micatin
 
Miconasil Nitrate
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Oravig
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
Rash Relief Antifungal
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
3
EpinephrineapprovedPhase 4, Phase 2, Phase 1, Phase 083451-43-45816
Synonyms:
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-dihydroxy-a-[(methylamino)methyl]-Benzyl alcohol
(-)-3,4-dihydroxy-alpha-[(methylamino)methyl]-Benzyl alcohol
(-)-Adrenalin
(-)-Adrenaline
(-)-Epinephrine
(-)-R-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-(−)-adrenaline
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-4-[1-hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
(R)-Adrenaline
(R)-Epinephrine
(−)-adrenaline
02252_FLUKA
1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
1-Adrenalin
1-Epinephrine
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
51-43-4
51-43-4 (FREE BASE)
51028-73-0
A0173
AC-13188
AC1L1L7B
ADR ADRENALINE
ADROP
AI3-19015
Adnephrine
Adrenaclick
Adrenal
Adrenalin
Adrenalin (TN)
Adrenalin in Oil
Adrenalin-Medihaler
Adrenalina
Adrenalina [DCIT]
Adrenaline
Adrenaline (JP15)
Adrenaline/Epinephrine
Adrenalinum
Adrenamine
Adrenan
Adrenapax
Adrenasol
Adrenatrate
Adrenine
Adrenodis
Adrenohorma
Adrenosan
Adrenutol
Adrin
Adrine
Ana-Guard
Ana-Kit
Antiasthmatique
Asmatane Mist
Asthma meter mist
Asthma-nefrin
Asthmahaler Mist
Asthmanefrin
Astmahalin
Astminhal
Auvi-q
BIDD:GT0119
Balmadren
Bernarenin
Biorenine
Bosmin
Brevirenin
Bronkaid
Bronkaid Mist
Bronkaid Suspension Mist
Bupivacaine Hcl and Epinephrine
C00788
CCRIS 4812
CHEBI:28918
CHEMBL679
CID5816
Chelafrin
Citanest Forte
Corisol
D-Epifrin
D-Epinephrine
D00095
DB00668
Drenamist
Dylephrin
Dyspne-Inhal
E4250_SIGMA
EINECS 200-098-7
EPI E Z PEN JR
EPIPEN E Z PEN
EPIPEN JR
Epi EZ Pen Jr
Epifrin
Epiglaufrin
Epinefrin
Epinefrin [Czech]
Epinefrina
Epinefrina [INN-Spanish]
Epinephran
Epinephrin
Epinephrine
Epinephrine (USP)
Epinephrine (USP/INN)
Epinephrine [USAN:INN:JAN]
Epinephrine bitartrate
Epinephrine chloride
Epinephrine hydrochloride
Epinephrinum
Epinephrinum [INN-Latin]
Epipen
Epipen (TN)
Epipen Auto-Injector
Epipen EZ Pen
Epipen Jr
Epipen Jr.
Epipen Jr. Auto-Injector
Epipen jr
Epirenamine
Epirenan
Epirenin
Epitrate
Eppy
 
Esphygmogenina
Exadrin
Glaucon
Glaucosan
Glauposine
Glycirenan
HSCI1_000215
HSDB 4289
Haemostasin
Haemostatin
Hektalin
Hemisine
Hemostasin
Hemostatin
Hypernephrin
Hyporenin
IOP
Intranefrin
Iontocaine
Isoptoepinal
Kidoline
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-Adrenaline Base
L-Epinehphrine
L-Epinephrine
L-Epirenamine
L-Methylaminoethanolcatechol
L-epinephrine
LS-156
Levo-Methylaminoethanolcatechol
Levoadrenaline
Levoepinephrine
Levorenen
Levorenin
Levorenine
Levoreninum
Lopac-E-4642
Lyodrin
Lyophrin
Medihaler-Epi
Metanephrin
Methylaminoethanolcatechol
Methylarterenol
Micronefrin
Micronephrine
MolPort-002-051-368
Mucidrina
Myosthenine
Mytrate
NCGC00015417-01
NCGC00142615-01
NCGC00142615-03
NCGC00142615-04
NCGC00142615-05
NCGC00142615-06
NCGC00142615-07
NSC 62786
NSC62786
Nephridine
Nieraline
PDSP1_001120
PDSP2_001104
Paranephrin
Primatene
Primatene Mist
Primatene Mist Refill
Prime Asthma Relief
R-(-)-Epinephrine
R-Adrenaline
RCRA waste no. P042
Racemic Epinephrine
Racepinephrine
Rcra waste number P042
Renagladin
Renaglandin
Renaglandulin
Renaleptine
Renalina
Renoform
Renostypricin
Renostypticin
Renostyptin
SMP1_000227
ST069368
SUS-PHRINE SULFITE-FREE
Scurenaline
Septocaine
Simplene
Sindrenina
Soladren
Sphygmogenin
Stryptirenal
Styptirenal
Supracapsulin
Supradin
Supranefran
Supranephrane
Supranephrine
Supranol
Suprarenaline
Suprarenin
Suprel
Surenine
Surrenine
Sus-Phrine
Sus-phrine
Susphrine
Sympathin I
Takamina
Takamine
Tokamina
Tonogen
Twinject
Twinject 0.15
Twinject 0.3
Twinject 0.30
UNII-YKH834O4BH
Vaponefrin
Vasoconstrictine
Vasoconstrictor
Vasodrine
Vasoton
Vasotonin
adrenaline
bmse000316
d-Adrenaline
epinephrine
l-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
l-Adrenalin
l-Adrenaline
l-Epinephine
l-Epinephrine (synthetic)
l-Epirenamine
l-Methylaminoethanolcatechol
levoepinephrine
nchembio747-comp9
4
DexmedetomidineapprovedPhase 4470113775-47-668602, 5311068, 56032
Synonyms:
(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-alpha,2,3-trimethylbenzyl)imidazole
(+)-medetomidine
(S)-medetomidine
113775-47-6
4-[(1S)-1-(2,3-Dimethylphenyl)ethyl]-1H-imidazole
4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
AC1NSJXT
C07450
CHEBI:4466
CHEMBL778
CID5311068
D00514
DEXMEDETOMIDINE
Dexdor (T)
 
Dexmedetomidin
Dexmedetomidina
Dexmedetomidine
Dexmedetomidine (USAN/INN)
Dexmedetomidine Hydrochloride
Dexmedetomidinum
Dexmédétomidine
MPV 1440
MPV-1440
Medetomidina [Spanish]
Medetomidine
Medetomidinum [Latin]
NCGC00025347-01
PRECEDEX
Precedex
Precedex (TN)
Tocris-2023
ZINC04632106
5
Sirolimusapproved, investigationalPhase 4, Phase 2, Phase 1179753123-88-95284616, 6436030, 46835353
Synonyms:
(-)-Rapamycin
(-)-rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC-722
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AY 22989
AY-22989
AY22989
Ambotz53123-88-9
Antibiotic AY 22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
 
FT-0082351
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MS-R001
MolMap_000043
MolPort-003-959-433
NCGC00021305-05
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
RPM
Rapammune
Rapamune
Rapamune (TN)
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin Immunosuppressant Drug
Rapamycin from Streptomyces hygroscopicus
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
SMP1_000255
SMR000058564
Sirolimus
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
WY-090217
Wy 090217
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
rapamycin
sirolimus
6
Bevacizumabapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 11875216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
7
BudesonideapprovedPhase 4, Phase 2, Phase 3, Phase 138151333-22-363006, 5281004
Synonyms:
(11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde
(RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione
(RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde
(S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione
16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione
16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione
16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione
16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
16alpha-,17alpha--butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione
51333-22-3
AC-4697
AC1L1DQE
AC1L1Y6Y
AC1L22VC
AC1MHWI7
B 7777
B7777_SIGMA
BPBio1_000523
BRD-A34299591-001-03-4
BRD-A82238138-001-01-7
BSPBio_000475
BSPBio_002160
Bidien
Bio-0010
Budecort Inhaler
Budenofalk
Budeson
Budesonide
Budesonide (JAN/USAN/INN)
Budesonide Easyhaler
Budesonide Inhalation
Budesonide MMX
Budesonide Nasal
Budesonide [USAN:INN:BAN:JAN]
Budesonido
Budesonido [INN-Spanish]
Budesonidum
Budesonidum [INN-Latin]
Budiair
Budicort
C25H34O6
CCRIS 5230
CHEBI:3207
CHEBI:656601
CHEMBL1370
CID2462
CID3033890
CID40000
CID5281004
CID63006
CPD000058337
Cortivent
D00246
DB01222
Desowen
Dexbudesonide
Dexbudesonide [INN]
DivK1c_000475
EINECS 257-139-7
EINECS 257-160-1
EINECS 257-161-7
EU-0100174
Entocort
Entocort EC
Entocort EC (TN)
Giona Easyhaler
HMS1569H17
HMS1921I22
HMS2094I13
HMS501H17
 
Horacort
IDI1_000475
Inflammide
KBio1_000475
KBio3_001660
KBioGR_001361
LS-187734
LS-7235
Lopac0_000174
MAP-0010
MLS000028507
MLS001077323
MLS002207112
Micronyl
Miflonide
MolPort-002-529-265
MolPort-003-666-332
MolPort-003-986-909
NCGC00015165-03
NCGC00021318-03
NCGC00021318-06
NCGC00089747-02
NCGC00089747-03
NCGC00089747-04
NCGC00178789-01
NINDS_000475
Noex
Preferid
Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-, and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
Prestwick0_000518
Prestwick1_000518
Prestwick2_000518
Prestwick3_000518
Prestwick_840
Pulmaxan
Pulmaxan turbohaler
Pulmicort
Pulmicort (TN)
Pulmicort FLEXHALER
Pulmicort Flexhaler
Pulmicort Nebuamp
Pulmicort Respules
Pulmicort Topinasal
Pulmicort Turbuhaler
Pulmicort turbuhaler
Respules
Rhinocort
Rhinocort Aqua
Rhinocort Turbuhaler
Rhinocort alpha
Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide
Rhinosol
S 1320
S-1320
S1286_Selleck
SAM002699898
SMR000058337
SPBio_000586
SPBio_002396
SPECTRUM1500813
ST51039033
Spectrum2_000623
Spectrum3_000620
Spectrum4_000821
Spectrum5_001738
Spirocort
TL8003397
Tridesilon
UDB
UNII-168L5HT37P
UNII-2HI1006KPH
UNII-Q3OKS62Q6X
Uceris
Unit dose budesonide
ZINC03938751
ZINC04097286
budesonide
8
KetorolacapprovedPhase 427866635-83-43826
Synonyms:
(+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
(+-)-Ketorolac
(+-)-isomer
(.+/-.)-2,3-Dihydro-5-benzoyl-1H-pyrrolizine-1-carboxylic acid
1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro
5-(phenylcarbonyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
5-Benzoyl-1,2-dihydro-3H-pyrrolo(1,2a)pyrrole-1-carboxylic acid
5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
66635-83-4
74103-06-3
AB00053682
AC-545
AC1L1GSW
Acular
Acuvail
BRD-A40639672-234-05-7
C07062
CHEBI:105080
CHEMBL469
CID3826
D020910
D08104
DB00465
 
I14-2832
Ketoralac
Ketorolac
Ketorolac (INN)
Ketorolac Tromethamine
Ketorolac [INN:BAN]
Ketorolaco
Ketorolaco [Spanish]
Ketorolacum
Ketorolacum [Latin]
Kétorolac
LS-139094
Macril
MolPort-005-933-093
NCGC00185990-01
RS 37619
RS-37619
SBB067312
STL018674
Sprix
Toradol (TN)
UNII-YZI5105V0L
ketorolac
rac-Ketorolac
9
PaclitaxelapprovedPhase 4, Phase 3, Phase 2, Phase 1, Phase 0262133069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
10
Heparinapproved, investigationalPhase 4, Phase 3, Phase 1, Phase 27199005-49-6772, 46507594
Synonyms:
101921-26-0
102-94-3
102785-31-9
104521-37-1
11078-24-3
11129-39-8
12656-11-0
2-o-sulfohexopyranuronosyl-(1->4)-2-deoxy-3-o-sulfo-2-(sulfoamino)hexopyranosyl-(1->4)-2-o-sulfohexopyranuronosyl-(1->4)-2-acetamido-2-deoxy-6-o-sulfohexopyranose
37324-73-5
6-[6-[6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-2-carboxy-4-hydroxy-5-sulfooxyoxan-3-yl]oxy-2-(hydroxymethyl)-5-(sulfoamino)-4-sulfooxyoxan-3-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid
9041-08-1
9045-22-1
9075-96-1
913079-23-9
91449-79-5
AC1L19ZN
AC1L1ROY
ALFA 87-120
ALFA 87-163
ALFA 87-198
ALFA 87-81
ALFA 88-247
AR-1E4539
Allocinnamic acid
Ardeparin
Ardeparin sodium
Arteven
Bemiparin
Bemiparin sodium
CID772
CID8784
CY 216
Calciparine
Certoparin
Clexane
Clivarin
Clivarine
Cy 222
D006495
D017984
DB00407
DB01225
Dalteparin
Dalteparin sodium
Depo-Heparin
EINECS 232-681-7
EMT 966
EMT 967
EMT-966
EMT-967
EMT966
EMT967
Enoxaparin
Enoxaparin sodium
Enoxaparine
Eparina
Eparina [DCIT]
FR 860
Fluxum
Fragmin A
Fragmin B
Fragmin IV
Fraxiparin
H 2149
HSDB 3094
Hed-heparin
Hep Flush Kit in plastic container
Hep-Lock
Hep-Lock U/P
Hep-lock
Heparin
Heparin CY 216
Heparin Lock Flush
Heparin Lock Flush in plastic container
Heparin Lock Flush preservative free
Heparin Lock Flush preservative free in plastic container
Heparin Sodium
Heparin natrium
Heparin sodium
Heparin sodium 1,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 1,000 units in dextrose 5% in plastic container
Heparin sodium 1,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 10,000 units in dextrose 5%
Heparin sodium 10,000 units in dextrose 5% in plastic container
Heparin sodium 10,000 units in sodium chloride 0.45%
Heparin sodium 10,000 units in sodium chloride 0.9%
Heparin sodium 12,500 units in dextrose 5%
Heparin sodium 12,500 units in dextrose 5% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.45% in plastic container
Heparin sodium 12,500 units in sodium chloride 0.9%
Heparin sodium 2,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 2,000 units in dextrose 5% in plastic container
Heparin sodium 2,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 20,000 units and dextrose 5% in plastic container
Heparin sodium 20,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units and dextrose 5% in plastic container
 
Heparin sodium 25,000 units in dextrose 5%
Heparin sodium 25,000 units in dextrose 5% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.45% in plastic container
Heparin sodium 25,000 units in sodium chloride 0.9%
Heparin sodium 25,000 units in sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units and sodium chloride 0.9% in plastic container
Heparin sodium 5,000 units in dextrose 5% in plastic container
Heparin sodium 5,000 units in sodium chloride 0.45%
Heparin sodium 5,000 units in sodium chloride 0.9%
Heparin sodium 5,000 units in sodium chloride 0.9% in plastic container
Heparin sodium in plastic container
Heparin sodium preservative Free
Heparin sulfate
Heparin sulphate
Heparin, Low Molecular Weight
Heparin, Low-Molecular-Weight
Heparin, sodium salt
Heparina
Heparina [INN-Spanish]
Heparinate
Heparine
Heparine [INN-French]
Heparinic acid
Heparinsodiumsalt
Heparinum
Heparinum [INN-Latin]
Heparinum natricum
Hepathrom
Hepflush-10
Inno-Hep
Innohep
Isocinnamic acid
KB 101
Kabi 2165
LHN 1
LMWH
Lioton 1000
Lipo-hepin
Liquaemin
Liquaemin Lock Flush
Liquaemin Sodium
Liquaemin sodium preservative free
Liquemin
Logiparin
Lovenox
Lovenox HP
Low Molecular Weight Heparin
Low molecular weight heparin
Low molecular weight heparin sodium
Low-Molecular-Weight Heparin
Minolteparin sodium
MolPort-003-760-257
Multiparin
NSC174025
Nadroparin
Nadroparine
Novoheparin
OP 386
OP 622
Octaparin
PK 10,169
PK-10,169
PK-10169
PK10,169
PK10169
Pabyrin
Panheprin
Parnaparin
Parnaparin sodium
Parvoparin
Pularin
Reviparin
Reviparin sodium
Ro 11
Sandoparin
Sodium acid heparin
Sodium heparin
Sodium heparinate
Subeparin
Sublingula
Thromboliquine
Tinzaparin
Tinzaparin sodium
Triofiban
UNII-12M44VTJ7B
UNII-3S182ET3UA
UNII-E47C0NF7LV
UNII-T2410KM04A
UNII-ZZ45AB24CA
Vetren
Vitrum AB
WY 90493RD
alpha-Heparin
cis-.beta.-Carboxystyrene
cis-Cinnamic acid
enoxaparin
heparin
11
EverolimusapprovedPhase 4, Phase 2, Phase 11797159351-69-66442177
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
Afinitor Disperz
CERTICAN(R)
CHEMBL1201755
Certican
D02714
DB01590
 
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD-001
RAD-001C
RAD001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
S1120_Selleck
SDZ-RAD
UNII-9HW64Q8G6G
VOTUBIA
Zortress
everolimus
12
Midazolamapproved, illicitPhase 4, Phase 163559467-70-84192
Synonyms:
4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluoro-phenyl)-1-methyl-, (Z)-2-butenedioate
59467-70-8
8-Chlor-6-(2-fluorphenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepin
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine
8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5a][1,4]benzodiazepine hydrochloride
8-Chloro-6-(O-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine
8-Chloro-6-(o-fluorophenyl)-1-methyl-4H-imidazo(1,5-a)(1,4)benzodiazepine
AC-18749
AC1L1HMA
BIDD:GT0647
BRN 0625572
Buccolam
C07524
C18H13ClFN3
CHEMBL655
CID4192
D00550
DB00683
DEA No. 2884
Dazolam
Dea No. 2884
Dormicum
 
Dormicum (TN)
EINECS 261-774-5
LS-77780
Midanium
Midazolam
Midazolam (JAN/INN)
Midazolam Base
Midazolam Hcl
Midazolam Hydrochloride
Midazolam [INN:BAN:JAN]
Midazolamum
Midazolamum [INN-Latin]
Midosed
MolPort-003-849-219
NCGC00168254-01
Ro 21-3981
TL8003787
UC429_SIGMA
UNII-R60L0SM5BC
Versed
ZINC00001732
midazolam
nchembio747-comp32
13
Fentanylapproved, illicit, investigationalPhase 4, Phase 3, Phase 2705437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Abstral
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl - Novaplus
Fentanyl Citrate
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
 
Fentanyl-12
Fentanyl-25
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Lazanda
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Subsys
UNII-UF599785JZ
fentanyl
14
NicotineapprovedPhase 4, Phase 3, Phase 2, Phase 197354-11-5942, 89594
Synonyms:
(−
(+)-Nicotine
(+-)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(+-)-Nicotine
(-)-3-(1-Methyl-2-pyrrolidyl)pyridine
(-)-3-(N-Methylpyrrolidino)pyridine
(-)-Nicotine
(-)-Nicotine solution
(2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine
(R)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(R,S)-Nicotine
(R,S)-nicotine
(RS)-nicotine
(S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE
(S)-(-)-Nicotine
(S)-3-(1-methylpyrrolidin-2-yl)pyridine
(S)-3-(N-methylpyrrolidin-2-yl)pyridine
(S)-Nicotine
(±)-nicotine
)-1-Methyl-2-(3-pyridyl)pyrrolidine
)-Nicotine
)-Nicotine solution
1-Methyl-2-(3-pyridal)-Pyrrolidine
1-Methyl-2-(3-pyridal)-pyrrolidene
1-Methyl-2-(3-pyridiyl)pyrrolidine
1-Methyl-2-(3-pyridyl)pyrrolidine
1uw6
2'-beta-H-Nicotine
3-(1-Methyl-2-pyrollidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)-Pyridine
3-(1-Methyl-2-pyrrolidinyl)pyridine
3-(1-Methylpyrrolidin-2-yl)pyridine
3-(2-(N-methylpyrrolidinyl))pyridine
3-(N-Methylpyrollidino)pyridine
3-(N-Methylpyrrolidino)pyridine
3-N-Methylpyrrolidine
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
36733_FLUKA
36733_RIEDEL
434F7990-3240-4A43-ACEC-E6CC1E495FA0
46343_FLUKA
46343_RIEDEL
54-11-5
AC1L3I79
AC1Q3ZOC
AI3-03424
American Fare Nicotine Transdermal System
BB_NC-0777
BIDD:GT0599
BRD-K05395900-322-02-1
Black Leaf
Black Leaf 40
C00745
CCRIS 1637
CHEBI:17688
CHEMBL3
CID89594
CPD000059074
Campbell's Nico-Soap
Careone Nicotine Transdermal System Step 1
Careone Nicotine Transdermal System Step 2
Careone Nicotine Transdermal System Step 3
Caswell No. 597
Commit
D-Nicotine
D03365
DL-tetrahydronicotyrine
Destruxol
Destruxol Orchid Spray
EINECS 200-193-3
ENT 3,424
EPA Pesticide Chemical Code 056702
Emo-Nik
Equaline Nicotine Transdermal System STEP 1
Exchange Select Nicotine Transdermal System STEP 3
Flux Maag
Fumeto bac
Fumetobac
HSDB 1107
Habitrol
Habitrol (TN)
Habitrol Patch Nicotine Transdermal System, Step 1
Habitrol Patch Nicotine Transdermal System, Step 2
Habitrol Patch Nicotine Transdermal System, Step 3
Healthmart Nicotine Transdermal System STEP 1
Healthmart Nicotine Transdermal System STEP 2
Healthmart Nicotine Transdermal System STEP 3
Kroger Nicotine Transdermal System STEP 1
Kroger Nicotine Transdermal System STEP 2
Kroger Nicotine Transdermal System STEP 3
L(-)-nicotine
L-3-(1-Methyl-2-pyrrolidyl)pyridine
L-Nicotine
LS-202
Leader Nicotine
Leader Nicotine Transdermal System STEP 1
Leader Nicotine Transdermal System STEP 2
Leader Nicotine Transdermal System STEP 3
MLS001055457
 
MLS001335905
Mach-Nic
Meijer Nicotine Transdermal System STEP 2
Meijer Nicotine Transdermal System Step 1
Meijer Nicotine Transdermal System Step 3
Methyl-2-pyrrolidinyl)pyridine
Micotine
MolPort-000-744-731
N3876_SIGMA
N5511_FLUKA
N5511_SIGMA
NCGC00090693-01
NCGC00090693-02
NCGC00090693-03
NCGC00090693-04
NCGC00090693-05
NCGC00090693-06
NCGC00090693-07
NCT
NICOTINE AND SALTS
NSC 5065
NSC97238
Niagara P.A. Dust
Nic-Sal
Nico-Dust
Nico-Fume
Nicocide
Nicoderm
Nicoderm CQ
Nicoderm Cq
Nicoderm Patch
Nicorette
Nicorette Plus
Nicotin
Nicotina
Nicotina [Italian]
Nicotine
Nicotine (USP)
Nicotine (compounds related to)
Nicotine Alkaloid
Nicotine Patch
Nicotine Polacrilex
Nicotine TRANSDERMAL SYSTEM
Nicotine Transdermal System PATCH KIT
Nicotine Transdermal System STEP 1
Nicotine Transdermal System STEP 2
Nicotine Transdermal System STEP 3
Nicotine Transdermal System Step 1
Nicotine Transdermal System Step 2
Nicotine Transdermal System Step 3
Nicotine [BSI:ISO]
Nicotine [UN1654]
Nicotine [UN1654] [Poison]
Nicotine [USAN]
Nicotine transdermal system
Nicotrol
Nicotrol (professional Sample)
Nicotrol Inhaler
Nicotrol Ns
Nictoine patch
Nikotin
Nikotin [German]
Nikotyna
Nikotyna [Polish]
Ortho N-4 Dust
Ortho N-5 Dust
PDSP1_000113
PDSP1_000465
PDSP2_000463
PDSP2_000555
Prostep
R)-(+)-Nicotine
RCRA waste no. P075
RCRA waste number P075
Rite Aid Nicotine Transdermal System Step 1
Rite Aid Nicotine Transdermal System Step 2
Rite Aid Nicotine Transdermal System Step 3
SAM002564224
SDCCGMLS-0066911.P001
SMR000059074
Safeway Nicotine Transdermal System STEP 1
Safeway Nicotine Transdermal System STEP 2
Safeway Nicotine Transdermal System STEP 3
Smart Sense Nicotine
Sunmark Nicotine
Sunmark Nicotine Transdermal System STEP 1
Sunmark Nicotine Transdermal System STEP 2
Sunmark Nicotine Transdermal System STEP 3
Tendust
Transdermal Nicotine
UN1654
a -N-Methylpyrrolidine
a-N-Methylpyrrolidine
alpha-N-Methylpyrrolidine
beta-Pyridyl-alpha-N-methyl pyrrolidine
beta-Pyridyl-alpha-N-methylpyrrolidine
bmse000105
delta-Nicotine
nicotine
nicotine replacement patch
15
Morphineapproved, investigationalPhase 4, Phase 3, Phase 185557-27-25288826
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(-)-Morphine
(-)Morphine sulfate
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5alpha,6alpha)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(−)-morphine
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
47106-99-0
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
8053-16-5
85201-37-2
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
CID5288826
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
DepoDur
Depodur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
HSDB 2134
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
Infumorph
 
Kadian
LS-91748
M-Eslon
M.O.S
MOI
MORPHINE SULFATE
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
MS Contin
MS/L
MS/S
MSIR
Meconium
MolPort-003-849-273
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
Morphine
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine Sulfate
Morphine [BAN]
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
Ms Emma
NSC11441
Nepenthe
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
RMS
RMS Uniserts
Rescudose
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
UNII-76I7G6D29C
Unkie
l-Morphine
morphine
nchembio.317-comp1
nchembio.64-comp1
16
DalteparinapprovedPhase 4, Phase 3, Phase 1, Phase 22819041-08-1
Synonyms:
Daltepariininatrium
Dalteparin Sodyum
Dalteparin sodium
Dalteparin sodná sůl
Dalteparin-nátrium
Dalteparina sódica
 
Dalteparinnatrium
Dalteparino natrio druska
Dalteparinum Natricum
Dalteparyna sodowa
Daltéparine sodique
Fragmin
Heparin Fragment KABI 2165
Tedelparin
17
EtoposideapprovedPhase 4, Phase 3, Phase 2, Phase 1116933419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
Eposin, Vepesid, VP-16, Toposar, Etoposide
 
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide Phosphate
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide
18
Modafinilapproved, investigationalPhase 4, Phase 2, Phase 119268693-11-84236
Synonyms:
Dea No. 1680
Modafinil
Modafinil [USAN:INN]
Modafinil [Usan:Inn]
Modafinilo
Modafinilo [Spanish]
 
Modafinilum
Modafinilum [Latin]
Moderateafinil
Modiodal
Provigil
Sparlon
modafinil
19
Amifostineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 18120537-88-62141
Synonyms:
Amifostina
Amifostine
Amifostine Ethiofos
Amifostinum
Aminopropylaminoethyl Thiophosphate
 
Apaetp
Ethiofos
Ethyol
Gammaphos
SAPEP
WR-1065
20
Dexamethasoneapproved, investigationalPhase 4, Phase 3, Phase 1, Phase 2190950-02-25743
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
137098-19-2
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16α-Methyl-9α-fluoro-1-dehydrocortisol
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-fluoro-16alpha-methyl-Prednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
AI3-50934
Adexone
Aeroseb-D
Aeroseb-Dex
Aeroseb-dex
Ak Dex Oph Otic Soln 0.1%
Alcon Brand of Dexamethasone
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (Veterinary)
Azium (veterinary)
BIDD:ER0494
BIDD:PXR0060
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
Baycadron
Bisu DS
Bisu Ds
C15643
C22H29FO5
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
CPD-10549
CPD001227192
Calonat
Corson
Corsone
Cortisumman
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
DEX
DEXA
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
DXM
DXMS
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-LA
Decadron-La
Decagel
Decaject
Decaject L.A.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [DCIT]
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
Dex-Ide
Dex-ide
Dexa
Dexa Mamallet
Dexa mamallet
Dexa-Cortidelt
Dexa-Cortisyl
Dexa-Mamallet
Dexa-Scheroson
Dexa-Sine
Dexa-cortidelt
Dexa-cortisyl
Dexa-scheroson
Dexa-sine
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexacortin
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
Dexameth
Dexamethansone
 
Dexamethasone
Dexamethasone (JP15/USP/INN)
Dexamethasone Acetate
Dexamethasone Alcohol
Dexamethasone Base
Dexamethasone Intensol
Dexamethasone Sodium Phosphate
Dexamethasone [INN:BAN:JAN]
Dexamethasone acetate
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
Dexamethasone sodium phosphate
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamethsone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexason
Dexasone
Dexasone 0.5mg
Dexasone 0.75mg
Dexasone 4mg
Dexasporin
Dexinolon
Dexinoral
Dexone
Dexone 0.5
Dexone 0.75
Dexone 1.5
Dexone 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
Dxms
ECR Brand of Dexamethasone
EINECS 200-003-9
FT-0080377
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy Brand of Dexamethasone
Gammacorten
HL-dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
Hexadecadrol
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Hexadrol elixir
Hl-Dex
Hl-dex
I06-1196
ICN Brand of Dexamethasone
IontoDex
Isopto-Dex
Isopto-dex
LS-7300
Lokalison F
Lokalison f
Loverine
Luxazone
MK 125
MLS001055412
MLS001332507
MLS001332508
Maxidex
Maxidex Ont 0.1%
Maxidex Sus 0.1%
Maxitrol
Mediamethasone
Merck Brand of Dexamethasone
Merz Brand 1 of Dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MolMap_000018
MolPort-003-846-433
Mymethasone
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
NCI60_003067
NSC 34521
NSC34521
Naquasone (veterinary)
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
OTO-104
Ocu-Trol
Ocu-trol
Oradexon
Ozurdex
PHL-dexamethasone
PMS-dexamethasone
Pet Derm III
Pet Derm Iii
Pet derm III
Pet-Derm Iii
Pms Dexamethasone Elixir 0.5mg/5ml
Policort
Posurdex
Prednisolon F
Prednisolon f
Prednisolone F
Prednisolone f
Prodex
S1322_Selleck
SAM002548948
SGCUT00126
SK-Dexamethasone
SK-dexamethasone
SMP1_000092
SMR000857119
SMR001227192
ST50307091
Sandoz dexamethasone
Sk-Dexamethasone
Spectrum5_002019
Spoloven
Sunia Sol D
Sunia sol D
Superprednol
TL8003317
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
alpha -Fluoro-16-alpha -methylcortisol
delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexamethasone
nchembio809-comp2
to_000038
21
Sunitinibapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1486341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib Malate
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
22
Irinotecanapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1104497682-44-5, 100286-90-660838
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
97682-44-5
AC-7469
AC1L1U0Z
AC1Q6PGI
BRD-K08547377-003-02-4
BSPBio_002346
Bio-0054
Biotecan
Biotecan (TN)
C16641
C33H38N4O6
CHEBI:105985
CHEMBL481
CID60838
CP0
Campothecin-11
Campto
Camptosar
 
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
D08086
DB00762
FT-0083650
HSDB 7607
IRINOTECAN HYDROCHLORIDE Trihydrate
IRINOTECAN, CPT-11
Irinotecan
Irinotecan (INN)
Irinotecan Hcl
Irinotecan Hydrochloride
Irinotecan Hydrochloride Trihydrate
Irinotecan [INN:BAN]
Irinotecan hydrochloride
Irinotecanum
Irinotecanum [INN-Latin]
LS-44589
NCI60_005051
NSC728073
S1198_Selleck
TL8006026
UNII-7673326042
irinotecan
23
Bupivacaineapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 19642180-92-92474
Synonyms:
( inverted exclamation markA)-bupivacaine
(+-)-Bupivacaine
(1)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
(RS)-bupivacaine
1-Butyl-2',6'-pipecoloxylidide
1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
15233-43-9
2180-92-9
38396-39-3
AB00053674
AC-2096
AC1L1DRE
AC1Q5LX4
AH 250
AKOS001637202
AR-1A0242
Anekain
BPBio1_000298
BRD-A01636364-003-05-2
BSPBio_000270
BSPBio_002607
Bio-0886
Bloqueina
Bucaine
Bucaine (TN)
Bupivacaina
Bupivacaina [INN-Spanish]
Bupivacaine
Bupivacaine (INN)
Bupivacaine Carbonate
Bupivacaine HCL
Bupivacaine HCL KIT
Bupivacaine Hydrochloride
Bupivacaine Monohydrochloride, Monohydrate
Bupivacaine [INN:BAN]
Bupivacainum
Bupivacainum [INN-Latin]
Bupivan
C07529
C18H28N2O
CBupivacaine
CHEBI:3215
CHEMBL1098
CID2474
Carbostesin
D07552
DB00297
DL-Bupivacaine
DUR-843
DepoBupivacaine
 
DivK1c_000758
EINECS 218-553-3
EINECS 253-911-2
Exparel
HMS2090F12
IDI1_000758
KBio1_000758
KBio2_002004
KBio2_004572
KBio2_007140
KBio3_001827
KBioGR_001516
KBioSS_002004
KST-1A4609
L000695
LAC-43
LS-109841
LS-2222
MLS001361336
Marcaina
Marcaine
Marcaine HCL
Marcaine Spinal
MolPort-004-955-820
NCGC00178579-01
NCGC00178579-02
NINDS_000758
NSC119660
Prestwick0_000305
Prestwick1_000305
Prestwick2_000305
Prestwick3_000305
Racemic bupivacaine
SMR000058218
SPBio_001558
SPBio_002489
Sensorcaine
Sensorcaine-MPF
Sensorcaine-MPF Spinal
Spectrum2_001589
Spectrum3_000974
Spectrum4_001098
Spectrum5_001483
Spectrum_001524
Transdur-Bupivacaine
UNII-Y8335394RO
Vivacaine
Win 11318
Win 11318 HCl
bupivacaine
cBupivacaine
dl-1-Butyl-2',6'-pipecoloxylidide
24
CrizotinibapprovedPhase 4, Phase 3, Phase 2, Phase 1, Phase 092877399-52-511626560, 10366136, 10366137, 10366138, 10366139, 10366140, 10366141
Synonyms:
(R)-Crizotinib
C-Met/HGFR Tyrosine Kinase Inhibitor PF-02341066
C-Met/Hepatocyte Growth Factor Receptor Tyrosine Kinase Inhibitor PF-02341066
Crizotinib
Crizotinibum
 
MET Tyrosine Kinase Inhibitor PF-02341066
PF 2341066
PF-02341066
PF-2341066
Xalkori
crizotinib
25
LidocaineapprovedPhase 4, Phase 2, Phase 3, Phase 11103137-58-63676
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
AKOS001026768
ARONIS23855
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
Afterburn
Akten
Alphacaine
Anestacon
Anestacon Jelly
BIDD:GT0342
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
Bikini Zone Medicated
Bikini Zone Medicated Creme
Bio-0767
Bio-scriptives Lidum
Bio-scriptives Lidum Hemorroidal (anorectal)
Bio-scriptives Lidum Topical Analgesic
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
Burn Relief Leader
C07073
C14H22N2O
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
CPD000058189
Cappicaine
Cito optadren
Comfortcaine
Cuivasil
Curacaine Transdermal Corporation
D00358
DB00281
Dalcaine
Dentipatch
Dentipatch (TN)
Derma Numb
DermaFlex
Desert Harvest Releveum
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Dr. Numb
Dr. Richs Numbing
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla
Emla Cream
Esracaine
FT-0082378
Gigi Anesthetic Numbing
Gravocain
H-releve Hemorrhoidal
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
Hawaiian Tropic
Hush Anesthetic
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L-Caine
L0156
L1026_SIGMA
L7757_SIGMA
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
LIDOPEN
LQZ
LS-805
Lanabiotic
 
Laryng-o-jet
Leostesin
Lida-Mantle
Lidall
Lidocaina
Lidocaina [INN-Spanish]
Lidocaine
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine 4% Cream
Lidocaine Carbonate
Lidocaine Hydrocarbonate
Lidocaine Hydrochloride
Lidocaine Monohydrochloride
Lidocaine [USAN:INN:JAN]
Lidocaine hydrochloride
Lidocainum
Lidocainum [INN-Latin]
Lidocare Mist
Lidocaton
Lidocream 4
Lidocream 5
Lidoderm
Lidoderm 5
Lidoject-1
Lidoject-2
Lifestyles Epic Male Genital Desensitizer
Lignocaine
Lignocainum
Lingocaine
Lmx4
Lmx5
Lopac-L-5647
Lopac0_000669
MLS000069724
MLS000758263
MLS001074177
Maricaine
Maybridge1_002571
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
NINDS_000174
NSC 40030
NSC40030
Norwood Sunburn Spray
Numb Master Topical Anesthetic
Numb Nuts
Ocean Potion Instant Burn Relief Ice
Octocaine
Octocaine-100
Octocaine-50
Plum Smooth Plumb Numb Gelee
Premjact Male Desensitizer Pound International
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Recticare
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
SPBio_001525
SPBio_002100
STK552033
Simplicity Desensitizing
Simply Numb Endure
Solarcaine
Solarcaine aloe extra burn relief cream
Solcain
Sole Serum
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
Spectrum_001118
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Walgreens Aloe Vera Pain Relieving
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocaine-mpf
Xylocard
Xylocitin
Xyloneural (free base)
Xylotox
Zcaine Fast Acting Anesthetic
Zilactin-L
Zingo
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
alpha-Diethylamino-2,6-dimethylacetanilide
alpha-diethylamino-2,6-dimethylacetanilide
lidocaine
nchembio.65-comp16
α-diethylamino-2,6-dimethylacetanilide
26
CarboplatinapprovedPhase 4, Phase 3, Phase 2, Phase 1, Phase 0188541575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
27
Pemetrexedapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Phase 0580150399-23-8446556, 60843
Synonyms:
(2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
(2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
137281-23-3
150399-23-8
1juj
2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID
AC1L1U1D
AC1L2PDW
AC1L98DY
AC1L9JT6
AC1OCF51
AC1Q5R1W
Alimta
Alimta (TN)
Bio-0078
C20H19N5O6.2Na
C20H21N5O6
CHEBI:195145
CHEBI:43746
CHEBI:474008
CHEMBL1200373
CHEMBL225072
CHEMBL59843
CID125891
CID394493
CID446556
CID60843
CID6918197
D03828
D07472
DB00642
Disodium N-(p-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-L-glutamate
HSDB 7316
 
I06-1253
I06-1294
I06-2128
L-Glutamic acid, N-(4-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-, disodium salt
LS-172988
LS-173384
LY 231,514
LY 231514
LY-231,514
LY-2315
LY-231514
LY231514
LY231514 disodium
LYA
N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid
NCGC00167517-01
NCI60_035021
NSC698037
Pemetrexed
Pemetrexed (INN)
Pemetrexed Disodium
Pemetrexed [INN:BAN]
Pemetrexed disodium
Pemetrexed disodium (USAN)
Pemetrexed disodium [USAN]
Rolazar
SID50112739
ST51053024
Tifolar
UNII-04Q9AIZ7NO
UNII-2PKU919BA9
disodium (2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate
disodium (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate
n-{4-[2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-d-glutamic acid
nchembio.108-comp6
28
BupropionapprovedPhase 4, Phase 3, Phase 2, Phase 130834841-39-9444
Synonyms:
( -)-2-(tert-Butylamino)-3'-chloropropiophenone
( -)-2-(tert-Butylamino)-3'-chlorpropiophenon
(+-)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone
(+-)-Bupropion
.alpha.-(tert-Butylamino)-m-chloropropiophenone
1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]propan-1-one
2-(Tert-Butylamino)-3'-chloropropiophenone
2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one
34841-36-6 (hydrochloride)
34841-39-9
34911-55-2
AB00053756
AC-197
AC1L198Y
AMFEBUTAMONE HCl
Amfebutamon
Amfebutamona
Amfebutamona [INN-Spanish]
Amfebutamone
Amfebutamonum
Amfebutamonum [INN-Latin]
Aplenzin
BPBio1_000042
BRD-A05186015-003-05-7
BRN 2101062
BSPBio_000038
BSPBio_002247
Budeprion
Buproban
Bupropion
Bupropion (INN)
Bupropion (Old RN)
Bupropion (USAN)
Bupropion Hcl
Bupropion Hydrochloride
Bupropion SR
Bupropion [INN:BAN]
Bupropion hydrocloride
C06860
CHEBI:3219
CHEMBL894
CID444
CPD000472526
D07591
DB01156
 
DivK1c_007050
Elont
HMS2051G10
HMS2089G14
Jsp006301
KBio1_001994
KBio2_002143
KBio2_004711
KBio2_007279
KBio3_001467
KBioGR_001168
KBioSS_002143
L000725
LS-122817
Lopac0_000166
MLS001424015
MolPort-003-845-432
NCGC00015122-06
NCGC00089751-02
NCI60_002714
NSC315851
Prestwick0_000249
Prestwick1_000249
Prestwick2_000249
Prestwick3_000249
SAM001246699
SMR000472526
SPBio_001817
SPBio_002257
SpecPlus_000954
Spectrum2_001659
Spectrum3_000644
Spectrum4_000614
Spectrum5_001406
Spectrum_001663
TL8002604
UNII-01ZG3TPX31
Wellbatrin
Wellbutrin
Wellbutrin SR
Wellbutrin XL
Wellbutrin Xl
Zyban
alpha-(tert-butylamino)-m-chloropropiophenone
amfebutamonum
bupropion
29
Alfentanilapproved, illicitPhase 43571195-58-951263
Synonyms:
5-26-13-00110 (Beilstein Handbook Reference)
70879-28-6 (hydrochloride)
71195-58-9
AC1L1ARM
AC1Q6F0S
ALFENTANIL
Alfenta
Alfentanil
Alfentanil (INN)
Alfentanil [INN:BAN]
Alfentanilum
Alfentanilum [INN-Latin]
Alfentanyl
BRN 1188293
C08005
CHEBI:127190
CHEBI:2569
 
CHEMBL634
CID51263
D07122
DB00802
DEA No. 9737
HSDB 6789
L001231
LS-119259
MolPort-004-285-887
N-(1-(2-(4-Ethyl-4,5-dihydro-5-oxotetrazolyl)ethyl)-4-(methoxymethyl)-4-piperidyl)-N-phenylpropionamid
N-(1-(2-(4-Ethyl-4,5-dihydro-5-oxotetrazolyl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilid
N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide
N-[1-[2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl]-4-(methoxymethyl)-4-piperidyl]propionanilide
N-[1-[2-(4-ethyl-5-oxotetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl]-N-phenylpropanamide
N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl}-N-phenylpropanamide
N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-[(methyloxy)methyl]piperidin-4-yl}-N-phenylpropanamide
Rapifen (TN)
UNII-1N74HM2BS7
30
Propofolapproved, investigationalPhase 4, Phase 2, Phase 39312078-54-84943
Synonyms:
2, 6-Diisopropylphenol
2,6 Diisopropylphenol
2,6-Bis(1-methylethyl)phenol
2,6-Bis(Isopropyl)-phenol
2,6-DIISOPROPYLPHENOL
2,6-Diisopropyl phenol
2,6-Diisopropylphenol
2,6-bis(1-methylethyl)-phenol
2,6-di(propan-2-yl)phenol
2078-54-8
28449-97-0
4-06-00-03435 (Beilstein Handbook Reference)
50356-15-5
AB00513968
AC-2038
AC1L1J9Y
AC1Q1OUI
AI3-26295
AM-149
Abbott Brand of Propofol
Alpha Brand of Propofol
Ampofol
Aquafol
Astra Brand of Propofol
AstraZeneca Brand of Propofol
BIDD:GT0436
BPBio1_000950
BPBio1_000969
BRD-K82255054-001-03-5
BRN 1866484
BSPBio_000862
Biomol-NT_000248
Braun Brand of Propofol
C07523
C12H18O
CAS-2078-54-8
CCRIS 9000
CHEBI:44915
CHEMBL526
CID4943
CPD-11437
CPD000059151
Curamed Brand of Propofol
D00549
D015742
D0617
D126608
D126608_ALDRICH
DB00818
DDS-04F
Diisopropylphenol
Dipravan
Diprivan
Diprivan (TN)
Diprivan Injectable emulsion
Disoprivan
Disoprofol
EINECS 218-206-6
EU-0100437
Fresenius Brand of Propofol
Fresenius Kabi Brand of Propofol
Fresofol
HMS1570L04
HMS2089O21
HMS2094E17
 
HSDB 7123
ICI 35,868
ICI 35868
ICI-35,868
ICI-35868
ICI35,868
ICI35868
InChI=1/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H
Ivofol
Jsp004266
Juste Brand of Propofol
LS-996
Lopac-D126608
Lopac0_000437
MLS001066348
MLS001335999
MLS002454360
MolPort-001-794-517
NCGC00015389-01
NCGC00015389-02
NCGC00015389-04
NCGC00015389-09
NCGC00091538-01
NCGC00091538-02
NCGC00091538-03
NCGC00091538-04
NCGC00091538-05
NCGC00091538-06
NSC 5105
NSC5105
PFL
Parnell Brand of Propofol
Pisa Brand of Propofol
Prestwick0_000931
Prestwick1_000931
Prestwick2_000931
Prestwick3_000931
Propofol
Propofol (JAN/USAN/INN)
Propofol Abbott
Propofol Fresenius
Propofol IDD-D
Propofol MCT
Propofol Rovi
Propofol [USAN:INN:BAN]
Propofol(2,6-Diisopropylphenol)
Propofol-Lipuro
Propofolum
Propofolum [Latin]
Rapinovet
Recofol
Rovi Brand of Propofol
S01-0189
SAM002264610
SMR000059151
SPBio_003031
SPECTRUM1505022
ST50405911
Schering Brand of Propofol
UNII-YI7VU623SF
W505102_ALDRICH
ZD-0859
ZINC00968303
Zeneca Brand of Propofol
ghl.PD_Mitscher_leg0.558
nchembio.552-comp7
propofol
31
Gefitinibapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1330184475-35-2123631
Synonyms:
184475-35-2
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
4-(3'-chloro-4'-Fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
AC-1556
AC1L3X0A
AKOS000280752
BCB03_000781
Bio-0046
C419708
CCRIS 9011
CHEBI:49668
CHEMBL939
CID123631
CU-00000000396-1
D01977
DB00317
DB07998
EC-000.2409
EN002708
FT-0081035
Gefitini
Gefitinib
Gefitinib (JAN/USAN/INN)
Gefitinib [USAN]
Gefitinib, Iressa, ZD1839
HMS2089B19
I01-1227
IRE
 
Iressa
Iressa (TN)
Iressa(TM)
Irressat
K00240
KBioSS_002241
Kinome_3321
Kinome_3322
LS-139916
MolPort-000-883-335
N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
NCGC00159455-02
NCGC00159455-03
NSC715055
S1025_Selleck
STK621310
UNII-S65743JHBS
ZD 1839
ZD-1839
ZD-1839, Iressa, Gefitinib
ZD1839
ZINC19632614
gefitinib
nchembio.117-comp18
nchembio866-comp14
32
CisplatinapprovedPhase 4, Phase 2, Phase 3, Phase 1, Phase 0254015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatin
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinol-aq
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
33
BenzocaineapprovedPhase 4, Phase 1, Phase 216841994-09-7, 94-09-72337
Synonyms:
(p-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
20/20 Topical Anesthetic
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
4-amino-benzoic acid ethyl ester
4-aminobenzoic acid ethyl ester
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
AE-562/40377256
AI3-02081
AKOS000119763
AR-1H9065
Acetate, Benzocaine
Aethoform
Aethylium paraminobenzoicum
Alcohol Prep Pads
Allegenal-m
Alpha-caine Topical Anesthetic
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anbesol Jr
Anbesol Maximum Strength
Anbesol Regular Strength
Anestenka
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthetic
Anesthone
Atopalm Oral Pain Relief
BB_SC-0019
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
Baby Anbesol
Baby Anestenka
Baby Sensigel
Baby Sensigel Night Time Formula
Baby Teething Oral Pain Reliever
Bactimicina For Sore Throat
Bencocaine Topical Anesthetic
Bensokain
Benz O Sthetic
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
Benzocaine
Benzocaine (USP/INN)
Benzocaine Acetate
Benzocaine Formate
Benzocaine Hydrobromide
Benzocaine Hydrochloride
Benzocaine Methanesulfonate
Benzocaine [INN:BAN]
Benzocainum
Benzocainum [INN-Latin]
Benzodent
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
Boil Ease
Boy Butter Desensitizing Lubricant
Boy Butter Extreme Desensitizing Lubricant
Boy Butter Extreme H2O Desensitizing Lubricant
Brace Relief
Budpak Baby Teething Oral Pain Reliever
Budpak Oral Maximum Strength
C07527
CAS-94-09-7
CHEBI:116735
CHEMBL278172
CID2337
Carmex Cold Sore Treatment External Analgesic
Caswell No. 430A
Cepacol Fizzlers
Cepacol Sensations Hydra
Cepacol Sensations Sore Throat Hydra citrus splash
Cepacol Sensations Warming
Certus Sting Relief Prep Pad
Chloraseptic
Chloraseptic Warming Sore Throat
Colgate Orabase
Comfortcaine Topical Anesthetic
Cvs Fast Acting Baby Teething
Cvs Maximum Strength
Cvs Maximum Strength Boil Relief
Cvs Oral Anesthetic
Cvs Pharmacy Instant Toothache
Cvs Pharmacy Maximum Strength
Cvs Pharmacy Mouth Sore Gel
Cvs Pharmacy Nighttime Oral Pain Relief
D001566
D00552
DB01086
Dental Relief
Dentek Instant Pain Relief Maximum Strength
Dermoplast
Diet Ayds
DivK1c_000932
Dollar General Toothache Relief
Dukal Sting Relief Pad
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
ETHYL-P-AMINOBENZOATE
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl Aminobenzoate
Ethyl PABA
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
Ethyl p-Aminobenzoate
Ethyl p-Aminophenylcarboxylate
Ethyl p-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
Finafta Baby
Finafta MultiOral
Formate, Benzocaine
Gelato Topical Anesthetic
Good Neighbor Pain Relief
Goodsense Oral Pain Relief
Gps Topical Anesthetic
Gumnumb Topical Anesthetic
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Heb Severe Toothache
Herbasoul Male Genital Desensitizer Cream
 
Hurricaine
Hurricaine Topical Anesthetic
Hurricaine Topical Anesthetic Gel
Hurricaine Topical Anesthetic Liquid
Hydrobromide, Benzocaine
Hydrochloride, Benzocaine
I05-0204
IDI1_000932
Identhesin
Insect Bite Relief
Instant Toothache Pain Relief
Intense Cvs Intense Toothache
Iodent Maximum Strength Oral Analgesic
Ismile Topical Anesthetic
Jianze Sting Relief Pads
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Kank-a Mouth Pain
Keloform
Kmart Smart Sense
Kroger Toothache Pain Relief
LS-35847
Leader Oral Analgesic
Little Colds Sore Throat Relief Melt Aways
MLS001331704
MLS002153970
Makesense Junior Pain Relief
Makesense Pain Relief
Male Desensitizer Pleasure Balm
Mandelay Male Genital Desensitizer
Mark 3
Methanesulfonate, Benzocaine
MolPort-000-871-526
Mouth Sore Medication
Mouth Sore Relief Applicator
Mouth Sore Relief Professional Strength
My Fair Baby Instant Pain Relief
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
NINDS_000932
NSC 122792
NSC 41531
NSC41531
NSC4688
Nene Dente
Norcain
Norcaine
Norcainum
Opahl
Opahl Dye Free
Oprea1_750694
Oprea1_827402
Ora-jel
Orabase-B
Orajel For All Mouth Sores Maximum Strength
Orajel For Cold Sores
Orajel For Toothache Maximum Strength
Orajel Instant Pain Relief Maximum Strength
Orajel Instant Pain Relief Regular Strength
Orajel Instant Relief For Teething Pain
Orajel Instant Relief For Teething Pain Cooling Cucumber
Orajel Instant Relief For Teething Pain Daytime Nighttime Twin Pack
Orajel Instant Relief For Teething Pain Longer Lasting
Orajel Maximum Strength
Orajel Nighttime Instant Relief For Teething Pain Longer Lasting Extra Strength
Orajel Severe Toothache Maximum Strength Fast-Acting Formula
Oral Analgesic Maximum Strength
Oral B Instant Pain Relief
Oral Gel Maximum Strength
Oral Pain Relief Anesthetic Anesthetic
Oral Pain Reliever
Oralabs Cold Sore Treatment
Orthesin
Otocain
Outgro
Pac-dent Top Gel
Pain Relief
Pain Relief Alcohol Swabs
Parathesin
Parathesin (TN)
Parathesine
Physicians Care Sting Relief Pad
Pleasure Balm Kama Sutra
Preboost
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Prestwick_991
Purelife Topical Anesthetic
Quality Choice Maximum Strength Oral Pain Relieving
Red Cross Oral Pain Relief
Rexall Maximum Strength
Rite Aid Baby Care
Rite Aid Liquid Anesthetic Oral Pain Relief
Rite Aid Maximum Strength
Rite Aid Oral Pain Reliever
Rite Aid Professional Strength
SMR000059025
SPBio_000134
SPBio_002844
SPECTRUM1500139
STK043620
Sally Hansen Ouch-relief Numbing Wipes
Sally Hansen Ouch-relief Wax Kit
Sally Hansen Ouch-relief Wax Strip Kit
Sensigel
Severe Oral Pain Reliever
Sheffield Baby Teething Gel
Sheffield Pain Relief
Shunga Male Genital Desensitizer
Slim Mint Gum
Solarcaine
Solu H
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
Spectrum_000074
Sting Relief Medicated Pad
Sting Relief Pads
Tanac
Terrasil Boil Pain Relief
Tiger Supply Inc Topical Anesthetic
Top Quality Mfg. Topical Anesthetic
Topcaine
Topcare Maximum Strength
Topical Anesthetic Banana
Topical Anesthetic Bubble Gum
Topical Anesthetic Cherry
Topical Anesthetic Mint
Topical Anesthetic Pina Colada
Topical Anesthetic Raspberry
Topical Anesthetic Strawberry
UNII-U3RSY48JW5
Ultracare Anesthetic Bubble Gum
Ultracare Anesthetic Butter Rum
Ultracare Anesthetic Creme de Menthe
Ultracare Anesthetic Pina Colada
Ultracare Anesthetic Walterberry
WLN: ZR DVO2
Walgreens Baby Teething
Walgreens Intense Toothache
Walgreens Maximum Strength
Walgreens Pain Relieving For Boils
Walgreens Severe Oral Pain Reliever
Walgreens Severe Toothache Relief
Winco Foods Maximum Strength Oral Analgesic
ZINC12358719
Zilactin-b
benzocaine
ethylaminobenzoate-4
h-4-abz-oet
nchembio.182-comp4
p-(Ethoxycarbonyl)aniline
p-Aminobenzoate
p-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
p-Carbethoxyaniline
p-Ethoxycarboxylic Aniline
p-Ethoxycarboxylic aniline
34
Vinorelbineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 135271486-22-160780, 44424639
Synonyms:
5'-Noranhydrovinblastine
71486-22-1
AC1L1KVK
AC1L1TWQ
AC1L75Q4
ANX-530
Ambap71486-22-1
BIDD:PXR0186
C45H54N4O8
CHEBI:480999
CHEMBL607994
CID355119
CID5311497
CID5672
CID60780
CID6426842
D08680
DB00361
Eunades
Exelbine
HMS2090E13
HSDB 7665
I06-0084
I06-0085
KW 2307
KW 2307 base
KW-2307
 
LS-97533
MolPort-006-822-661
MolPort-006-823-869
NCGC00165966-02
NVB
Navelbine
Navelbine (TN)
Navelbine Base
Navelbine base
Nor-5'-anhydrovinblastine
SDP-012
UNII-Q6C979R91Y
Vinorelbin
Vinorelbina
Vinorelbina [Spanish]
Vinorelbine
Vinorelbine (INN)
Vinorelbine Bitartrate
Vinorelbine Ditartarate
Vinorelbine Ditartrate
Vinorelbine Tartrate
Vinorelbine [INN:BAN]
Vinorelbine ditartrate
Vinorelbine tartrate
Vinorelbinum
Vinorelbinum [Latin]
methyl (2b,3b,4b,5a,12b,19a)-4-(acetyloxy)-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate
methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate
vinorelbine
35
GemcitabineapprovedPhase 4, Phase 2, Phase 3, Phase 1188195058-81-460750
Synonyms:
103882-84-4
122111-03-9
2',2'-DiF-dC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFDC
DFdC
DFdCyd
Folfugem
GEO
Gamcitabine
GemLip
Gemcel
 
Gemcin
Gemcitabin
Gemcitabina
Gemcitabina [INN-Spanish]
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine Hydrochloride
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
Gemzar (hydrochloride)
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY-188011
LY188011
NCGC00168784-01
NChemBio.2007.10-comp25
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
ZINC18279854
Zefei
gemcitabine
nchembio.573-comp7
nchembio.90-comp2
36
Amiodaroneapproved, investigationalPhase 4, Phase 31141951-25-32157
Synonyms:
(2-Butyl-3-benzofuranyl)(4-(2-(diethylamino)ethoxy)-3,5-diidophenyl)methanone
(2-butyl-1-benzofuran-3-yl)(4-{[2-(diethylamino)ethyl]oxy}-3,5-diiodophenyl)methanone
(2-butyl-1-benzofuran-3-yl)-[4-(2-diethylaminoethyloxy)-3,5-diiodophenyl]methanone
(2-butyl-1-benzofuran-3-yl){4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl}methanone
(2-butylbenzofuran-3-yl)-[4-(2-diethylaminoethoxy)-3,5-diiodo-phenyl]-methanone
(2-{4-[(2-butyl-1-benzofuran-3-yl)carbonyl]-2,6-diiodophenoxy}ethyl)diethylamine
1951-25-3
2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran
2-Butyl-3-(3,5-diiodo-4-(beta-diethylaminoethoxy)benzoyl)benzofuran
2-Butyl-3-(4'-beta-N-diethylaminoethoxy-3',5'-diiodobenzoyl)benzofuran
2-Butyl-3-[3,5-diiodo-4-(2-di
2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone
2-Butyl-3-benzofuranyl p-((2-diethylamino)ethoxy)-m,m-diiodophenyl ketone
2-Butyl-3-benzofuranyl p-[(2-diethylamino)ethoxy]-m,m-diiodophenyl ketone
2-N-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran
2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran
5-18-02-00353 (Beilstein Handbook Reference)
AB00053422
AC1L1D1R
AC1Q2VCU
ASTA Medica Brand of Amiodarone Hydrochloride
Alphapharm Brand of Amiodarone Hydrochloride
Amidorone
Aminodarone
Amio-Aqueous IV
Amiobeta
Amiodarex
Amiodarona
Amiodarona [INN-Spanish]
Amiodarone
Amiodarone (USAN/INN)
Amiodarone Base
Amiodarone HCL
Amiodarone Hydrochloride
Amiodarone [USAN:BAN:INN]
Amiodarons
Amiodaronum
Amiodaronum [INN-Latin]
Amiohexal
Amjodaronum
Ancar
Aratac
Armstrong Brand of Amiodarone Hydrochloride
Arycor
BIDD:GT0425
BIDD:PXR0146
BPBio1_000372
BRN 1271711
BSPBio_000338
BSPBio_001574
BSPBio_002580
Berenguer Infale Brand of Amiodarone Hydrochloride
Betapharm Brand of Amiodarone Hydrochloride
Bio1_000026
Bio1_000515
Bio1_001004
Bio2_000294
Bio2_000774
Braxan
C06823
C25H29I2NO3
CAS-19774-82-4
CBiol_001740
CHEBI:2663
CHEMBL633
CID2157
Corbionax
Cordarex
Cordarone
Cordarone Intravenous
D000638
D02910
DB01118
DivK1c_000079
EINECS 217-772-1
G Gam Brand of Amiodarone Hydrochloride
 
HMS1791O16
HMS1989O16
HMS2089C07
Hexal Brand of Amiodarone Hydrochloride
IDI1_000079
IDI1_034044
KBio1_000079
KBio2_000294
KBio2_000741
KBio2_002862
KBio2_003309
KBio2_005430
KBio2_005877
KBio3_000587
KBio3_000588
KBio3_001800
KBioGR_000294
KBioGR_001859
KBioSS_000294
KBioSS_000741
Ketone, 2-butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl
Ketone, 2-butyl-3-benzofuranyl 4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl (7CI,8CI)
Kordaron
L 3428
L-3428
L001174
L3428
LS-87088
Labaz
Leurquin Brand of Amiodarone Hydrochloride
Lopac-A-8423
Lopac0_000122
MolPort-003-703-670
NCGC00015096-01
NCGC00015096-02
NCGC00015096-03
NCGC00015096-10
NCGC00024242-03
NCGC00024242-04
NCGC00024242-05
NCGC00024242-06
NCI60_041885
NINDS_000079
Nexterone
Ortacrone
Pacerone
Pharma Investi Brand of Amiodarone Hydrochloride
Prestwick0_000409
Prestwick1_000409
Prestwick2_000409
Prestwick3_000409
QTL1_000008
Rytmarone
SKF 33134-A
SKF 33134A
SPBio_001825
SPBio_002277
STK529812
STOCK1S-12240
Sanofi Winthrop Brand of Amiodarone Hydrochloride
Sedacoron
Sedacorone
Spectrum2_001813
Spectrum3_001050
Spectrum4_001190
Spectrum5_001533
Spectrum_000261
Tachydaron
UNII-N3RQ532IUT
UNM000001215003
Wyeth Brand of Amiodarone Hydrochloride
amiodarone
ethylaminoethoxy)benzoyl]benzofuran
nchembio.79-comp9
nchembio732-comp1
on
pms-Amiodarone
37
Aprepitantapproved, investigationalPhase 4, Phase 3, Phase 2154170729-80-3151165, 6918365
Synonyms:
170729-80-3
221350-96-5
3-(((2R,3S)-3-(P-Fluorophenyl)-2-(((alphar)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(2)-1,2,4-triazolin-5-one
3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-Delta(2)-1,2,4-triazolin-5-one
3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(sup 2)-1,2,4-triazolin-5-one
5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one
5-[[(2S,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one
5-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-one
AC1L45SL
AC1OCFCG
Aprepitant
Aprepitant (JAN/USAN/INN)
Aprepitant [USAN]
Aprepitantum
Aprépitant
CHEBI:323967
CHEBI:499361
CHEMBL135613
CHEMBL1471
CHEMBL249465
CID11214788
CID11318675
 
CID151165
CID6918365
CID9936947
CID9936948
D02968
DB00673
Emend
Emend (TN)
HMS2090N12
I06-1151
L 754030
L-754030
LS-156477
MK 0869
MK 869
MK-0517
MK-0869
MK-869
MK-869, L-754030, Emend, Aprepitant
MolPort-006-392-367
NCGC00181785-01
ONO-7436
S1189_Selleck
UNII-1NF15YR6UY
38
AcetylcysteineapprovedPhase 4293616-91-112035
Synonyms:
(2R)-2-acetylamino-3-Sulfanylpropanoic acid
(R)-2-acetylamino-3-Mercaptopropanoic acid
(R)-Mercapturic acid
2-Acetylamino-3-mercapto-propionate
2-Acetylamino-3-mercapto-propionic acid
ACC
Acetadote
Acetilcisteina
Acetylcysteine
Acetylcysteinum
Fluimicil Infantil
Fluimucetin
Fluimucil
Flumucetin
 
Fluprowit
L-Acetylcysteine
L-alpha-acetamido-beta-Mercaptopropionic acid
Lysox
Mercapturic acid
Mucolysin
Mucomyst
N-ACETYL-L-cysteine
N-Acety-L-Cysteine
N-Acetyl-3-mercaptoalanine
N-Acetyl-L-(+)-cysteine
N-Acetylcysteine
N-acetylcysteine
NAC
Parvolex
Sodium 2-acetamido-3-mercaptopropionate
39
RemifentanilapprovedPhase 4409132875-61-760815
Synonyms:
1-Piperidinepropanoic acid, 4-(methoxy-carbonyl)-4-((1-oxopropyl)phenylamino)-, methyl ester
132539-07-2 (mono-hydrochloride)
132875-61-7
3-(4-methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic acid methyl ester
4-carboxy-4-(n-phenylpropionamido)-1-piperidinepropionic acid dimethyl ester
AC1L1TZ8
AC1Q5ZGR
BIDD:GT0029
C08021
CHEBI:8802
CHEMBL1005
CID60815
D08473
DB00899
 
DEA No. 9739
GI 87084B
GI 87084X
GI87084B
L001266
LS-115982
MolPort-004-286-006
REMIFENTANIL
Remifentanil (INN)
Remifentanil [INN:BAN]
Remifentanyl
UNII-P10582JYYK
Ultiva
Ultiva (TN)
methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate
40
OndansetronapprovedPhase 4, Phase 328599614-02-54595
Synonyms:
(RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one
1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one
103639-04-9 (mono-hydrochloride dihydrate)
108303-49-7
116002-70-1
9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one
9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one
9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
99614-01-4 (mono-hydrochloride)
99614-02-5
AB00373674
AC1L1IIM
AKOS000599484
Apo-ondansetron
BAS 00717177
BPBio1_001118
BRD-A19736161-001-01-8
BRD-A19736161-003-03-0
BRN 3622981
BSPBio_001016
C07325
C18H19N3O
CBDivE_008994
CHEMBL46
CID4595
CPD001307702
D00456
DB00904
DESMETHYLONDANSETRON
GR 38032
GR 38032X
GR-38032F
GR38032F
HMS2090H16
I06-0687
I06-1329
L000456
 
LS-172305
LS-51878
MolPort-001-944-253
NCI60_022780
Novo-ondansetron
Ondansetron
Ondansetron (JAN/USP/INN)
Ondansetron Hydrochloride
Ondansetron [USAN:INN:BAN]
Ondansetron hydrochloride dihydrate
Ondansetron, (+,-)-Isomer
Oprea1_435466
Oprea1_852372
PHL-ondansetron
PMS-ondansetron
Prestwick0_001058
Prestwick1_001058
Prestwick2_001058
Prestwick3_001058
Ratio-ondansetron
SAM002589958
SN-307
SPBio_002938
STK370548
STOCK4S-10990
Sandoz ondansetron
TL8006071
TimTec1_001750
UNII-4AF302ESOS
ZOFRAN IN PLASTIC CONTAINER
Zofran
Zofran ODT
Zofran ODT (TN)
Zofran odt
Zophren
Zudan
Zuplenz
ondansetron
ondansetron (Zofran)
41
FosaprepitantapprovedPhase 4, Phase 3, Phase 2154172673-20-0219090
Synonyms:
Fosaprepitant dimeglumine
 
Fosaprepitantum
L-758,298
L-758298
42
TerbutalineapprovedPhase 43923031-25-65403
Synonyms:
(+-)-5-(2-((1,1-Dimethylethyl)amino)-1-hydroxyethyl)-1,3-benzenediol
(+-)-Terbutaline
1,3-Benzenediol, 5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)- (9CI)
23031-25-6
23031-32-5 (Sulfate)
46719-29-3
5-(2-((1,1-DIMETHYLETHYL)AMINO)-1-HYDROXYETHYL)-1,3-BENZENEDIOL
5-[2-(tert-butylamino)-1-hydroxyethyl]benzene-1,3-diol
5-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}benzene-1,3-diol
AB00053548
AC1L1KA2
Asthmasian
Asthmasian (TN)
BPBio1_000663
BRD-A50157456-065-02-4
BRN 2370513
BSPBio_000601
BSPBio_002066
Brethaire
Brethine
Brican
Bricanyl
Bricar
Bricaril
Bricyn
C07129
CHEMBL1760
CID5403
D08570
DB00871
DivK1c_000078
EINECS 245-385-8
I01-3464
IDI1_000078
KBio1_000078
KBio2_001510
KBio2_004078
KBio2_006646
KBio3_001566
KBioGR_001539
KBioSS_001510
 
KWD 2019
KWD-2019
L000594
LS-29961
LS-7713
Lopac0_001126
MolPort-003-850-418
NCGC00016010-06
NCGC00089821-02
NINDS_000078
Oprea1_823972
PDSP1_000158
PDSP2_000157
Prestwick0_000391
Prestwick1_000391
Prestwick2_000391
Prestwick3_000391
SBB063955
SPBio_001453
SPBio_002522
Spectrum2_001327
Spectrum3_000593
Spectrum4_000870
Spectrum5_001262
Spectrum_001030
Terbutalin
Terbutalina
Terbutalina [DCIT]
Terbutalina [Dcit]
Terbutaline (INN)
Terbutaline (sulfate de)
Terbutaline Sulfate
Terbutaline [INN:BAN]
Terbutaline sulfate
Terbutalini sulfas
Terbutalino
Terbutalino [INN-Spanish]
Terbutalinsulfat
Terbutalinum
Terbutalinum [INN-Latin]
UNII-N8ONU3L3PG
terbutaline
43
Nabiloneapproved, investigationalPhase 41651022-71-05284592
Synonyms:
Cesamet
Nabilon
 
Nabilona
Nabilone
Nabilonum
44
Vitamin Aapproved, nutraceuticalPhase 4, Phase 2, Phase 141311103-57-4, 68-26-8445354
Synonyms:
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol
(2e,4e,6e,8e)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol
(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
.alpha.lin
.alpha.sterol
.beta.-Retinol
11103-57-4
13123-33-6
1341-18-0
1406-67-3
17104-91-5
1rbp
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,4,6,8-nonatetraen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonate-traen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraen-1-ol
3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-E)-Isomer
4-06-00-04133 (Beilstein Handbook Reference)
53637-36-8
5979-23-7
68-26-8
95144_FLUKA
95144_SIGMA
95146_FLUKA
95146_SIGMA
A-Mulsal
A-Sol
A-Vi-Pel
A-Vitan
AC-11701
AC1L9HU3
AC1Q7BU9
ACON
ALL-TRANS RETINOL (SEE ALSO RETINOID PROJECT 1)
AR-1L3057
ATAV
Afaxin
Agiolan
Agoncal
Alcohol 9,13-dimethyl-7-(1,1,5-trimethyl-6-cyclohexen-5-yl)-7,9,11,13-nonatetraen-15-ol
Alcovit A
All Trans Retinol
All-trans retinol
All-trans-Retinol
Alphalin
Alphasterol
Anatola
Anatola A
Anti-infective vitamin
Antixerophthalmic vitamin
Antixerophthalmisches Vitamin
Aoral
Apexol
Apostavit
Aquasol A
Aquasol A Parenteral
Aquasynth
Atars
Avibon
Avita
Avitol
Axerol
Axerophthol
Axerophtholum
BIDD:PXR0102
BRN 0403040
Bentavit A
Biosterol
C00473
C17276
C20H30O
CCRIS 5444
CHEBI:17336
CHEMBL986
CID445354
Chocola A
Chocola a
Cylasphere
D014801
D06543
DB00162
Del-VI-A
Disatabs Tabs
Dofsol
Dohyfral A
EINECS 200-683-7
EINECS 234-328-2
Epiteliol
HMS1921B04
HMS2092L13
HMS501I08
HSDB 815
Hi-A-Vita
Homagenets Aoral
Homagenets aorl
Hydrovit A
IDI1_000486
LMPR01090001
LPK
LS-1578
Lard Factor
M.V.C. 9+3
M.V.I.-12
 
MLS001066379
MLS001074751
MolPort-001-785-962
Mvc Plus
Myvpack
NCGC00091784-01
NCGC00091784-02
NCGC00091784-03
NCGC00091784-04
NCGC00091784-05
NCGC00091784-06
NSC 122759
NSC122759
Nio-A-Let
Oleovitamin A
Ophthalamin
Plivit A
Prepalin
R7632_SIGMA
Retin-11,12-t2-ol (9CI)
Retinol
Retinol [INN:BAN]
Retinol solution
Retinol, all-trans- (8CI)
Retinol-(cellular-retinol-binding-protein)
Retinolo
Retinolo [DCIT]
Retinolum
Retinolum [INN-Latin]
Retrovitamin A
Ro-a-vit
Rovimix A 500
SDCCGMLS-0066724.P001
SMP2_000102
SMR000112036
SPECTRUM1501203
ST057232
Sehkraft A
Solu-A
Spectrum5_000993
Spectrum5_001997
Super A
Testavol
Testavol S
Thalasphere
UNII-81G40H8B0T
UNII-G2SH0XKK91
Vaflol
Vafol
Veroftal
Vi-.alpha.
Vi-Alpha
Vi-Dom-A
Vi-a
Vio-A
Vitamin A
Vitamin A (Feed)
Vitamin A (USP)
Vitamin A alcohol
Vitamin A alcohol (VAN)
Vitamin A cryst
Vitamin A palmitate
Vitamin A1
Vitamin A1 alcohol
Vitamin A1 alcohol, all trans
Vitamin a
Vitamin- A
Vitamin- A alcohol
Vitamin- A alcohol solution
Vitamin- A1
Vitamin-?A
Vitamin-?A alcohol
Vitamin-?A alcohol solution
Vitamin-?A1
Vitamine A
Vitaminum A
Vitavel A
Vitavel-A
Vitpex
Vogan
Vogan-Neu
Vogan-nu
WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U2Q C1 C1
Wachstumsvitamin
ZINC03831417
Zinosan N
[11,12-3H]-Retinol
alin
all-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
all-trans-Retinol
all-trans-Retinyl alcohol
all-trans-Vitamin A
all-trans-Vitamin A alcohol
all-trans-Vitamin A1
all-trans-retinol
all-trans-retinyl alcohol
all-trans-vitamin A alcohol
b-Retinol
beta-Retinol
retinol
tROL
trans-Retinol
trans-Retinol acid (Vitamin A)
trans-Vitamin A alcohol
trans-retinol
45
Caffeineapproved, NutraceuticalPhase 433958-08-22519
Synonyms:
07E4FB58-FD79-4175-8E3D-05BF96954522
1,3,7-Trimethyl-2,6-dioxopurine
1,3,7-Trimethyl-3,7-dihydro-1H-purine-2,6-dione
1,3,7-Trimethylpurine-2,6-dione
1,3,7-Trimethylxanthine
1,3,7-trimethylpurine-2,6-dione
1,3,7-trimethylxanthine
1-3-7-TRIMETHYLXANTHINE
1-Methyl-Theobromine
1-methyltheobromine
137X
1gfz
1l5q
1l7x
27602_FLUKA
2a3b
3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion
3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione
3,7-dihydro-1,3,7-trimethyl-1H-purine
5-26-13-00558 (Beilstein)
58-08-2
7-Methyl Theophylline
7-Methyltheophylline
7-methyltheophylline
71701-02-5
75035_FLUKA
95789-13-2
A.S.A. and Codeine Compound
AC-12774
AC1L1DV2
AC1Q3Z23
ACon1_000085
AI3-20154
AKOS000121334
Alert
Alert-Pep
Alert-pep
Allertness Aid
Anacin Maximum Strength
Anhydrous caffeine
Anhydrous caffeine (JP15)
Anhydrous caffeine (TN)
Anoquan
Awake
BIDD:ER0554
BIDD:GT0632
BIDD:PXR0172
BIM-0050216.0001
BRD-K02404261-001-02-7
BRD-K02404261-001-03-5
BRN 0017705
BSPBio_001921
Berlin-Chemie Brand of Caffeine
Bio-0579
Bio1_000473
Bio1_000962
Bio1_001451
Bristol-Myers Squibb Brand of Caffeine
C 0750
C07481
C0750_SIAL
C1778_SIAL
C2042
C6035_FLUKA
C6035_SIGMA
C7731_SIAL
C8960_SIAL
CCRIS 1314
CFF
CHEBI:27732
CHEMBL113
CID2519
CU-01000012617-3
Cafamil
Cafcit
Cafecon
Cafeina
Cafergot
Cafeína
Caffedrine
Caffedrine Caplets
Caffein
Caffeina
Caffeina [Italian]
Caffeine
Caffeine (USP)
Caffeine (natural)
Caffeine Citrate
Caffeine Pure
Caffeine [BAN:JAN]
Caffeine citrate
Caffeine solution
Caffeine, Anhydrous
Caffeine, Monohydrate
Caffeine, Synthetic
Caffeine, anhydrous
Caffeine, synthetic
Caffine
Cafipel
Caféine
Circle K Nosnooze
Coffein
Coffein [German]
Coffeine
Coffeinum
Coffeinum N
Coffeinum Purrum
Compound 65
Conrx Alert
D002110
D00528
DB00201
DHC Plus
DHCplus
Darvon Compound
Darvon Compound-65
Dasin
Dexitac
Dexitac Stay Alert Stimulant
Dhc Plus
Diurex
Diurex Ultra
Diurex WaterCaps
DivK1c_000730
Drowz Away Maximum strength
Durvitan
EINECS 200-362-1
EU-0100228
Eldiatric C
Enerjets
Equaline Stay Awake
Ercatab
Esgic
Esgic-Plus
FEMA No. 2224
Femcet
Fioricet
Fiorinal
GlaxoSmithKline Brand of Caffeine
Good Neighbor Pharmacy Stay Awake
Good Sense Stay Awake
Guaranine
HMS1920I09
HMS2091O11
HMS502E12
HSDB 36
Health Mart Stay Awake
Healthy Accents Stay Awake
Hycomine
Hycomine Compound
I14-4386
IDI1_000730
 
Invagesic
Invagesic Forte
KBio1_000730
KBio2_001781
KBio2_004349
KBio2_006917
KBio3_001141
KBioGR_002325
KBioSS_001781
Keep Alert
Kofein
Kofein [Czech]
Koffein
Koffein [German]
L000155
LS-237
Lanorinal
Leader Alertness Aid
Lil Drug Store Nosnooze
Lopac-C-0750
Lopac0_000228
MEGxp0_001350
MLS001055341
MLS001056714
MLS001066409
Mateina
Mateína
Maximum Strength Caffeine
Maximum Strength Snapback Stimulant Powders
Maximum Strength Stay Awake
Medigesic Plus
Merck dura Brand of Caffeine
Methyltheobromide
Methyltheobromine
Methylxanthine theophylline
Midol Maximum Strength
Migergot
Miudol
MolMap_000054
MolPort-000-730-850
Monohydrate Caffeine
Monomethyl Derivative of Theophylline
Monomethyl derivative of Theophylline
NCGC00015208-01
NCGC00015208-02
NCGC00015208-04
NCGC00015208-14
NCGC00090699-01
NCGC00090699-02
NCGC00090699-03
NCGC00090699-04
NCGC00090699-05
NCGC00090699-06
NCGC00090699-07
NCGC00090699-08
NCGC00090699-09
NCGC00168808-01
NCGC00168808-02
NCI-C02733
NCIOpen2_008255
NINDS_000730
NSC 5036
NSC5036
Nano Ppc
Natural Caffeinum
Nix Nap
No Doz
No-Doz
Nodaca
Nodoz Maximum Strength Caplets
Norgesic
Norgesic Forte
Organex
Orphengesic
Orphengesic Forte
P-A-C Analgesic Tablets
PDSP1_001016
PDSP1_001235
PDSP2_001000
PDSP2_001219
Passauer Brand of Caffeine
Pep-Back
Pep-back Peak Performance
Pep-back Ultra
Percoffedrinol N
Percutafeine
Phensal
Pierre Fabre Brand of Caffeine
Probes1_000150
Probes2_000128
Propoxyphene
Propoxyphene Compound 65
Propoxyphene Compound-65
Quick Pep
Quick-Pep
Refresh'n
Republic Drug Brand of Caffeine
SDCCGMLS-0064595.P001
SDCCGMLS-0064595.P002
SK 65 Compound
SK-65 Compound
SMR000326667
SPBio_001222
SPECTRUM1500155
STK177283
Seid Brand of Caffeine
Smart Sense Stay Awake
Sohmed Alertness Aid
Spectrum2_001261
Spectrum3_000321
Spectrum4_001782
Spectrum5_000423
Spectrum_001301
Stay Alert Aid
Stay Awake
Stay Awake Maximum Strength
Stay Awake Maximum strength
Stim
Sunmark Stay Awake
Synalgos-Dc
TNP00310
Teina
Thein
Theine
Theobromine ME
Theobromine Me
Theophylline ME
Theophylline Me
Theophylline, 7-methyl
Thompson Brand 1 of Caffeine
Thompson Brand 2 of Caffeine
Tirend
Topcare Stay Awake maximum strength
Tri-Aqua
Triad
UNII-3G6A5W338E
Ultra Pep-Back
Vivarin
W222402_ALDRICH
WLN: T56 BN DN FNVNVJ B1 F1 H1
Wake-Up
Wigraine
Xanthine, 1,3,7-trimethyl
ZINC00001084
bmse000206
cafeine
caffeine
caffenium
component of Cafergot
nchembio.243-comp7
nchembio.63-comp5
nchembio774-comp2
teina
46
Folic Acidapproved, nutraceuticalPhase 4, Phase 3, Phase 2, Phase 1, Phase 0292459-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic Acid
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
 
Folsaeure
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
47
Docetaxelapproved, investigational, Approved May 1996Phase 4, Phase 3, Phase 2, Phase 1, Phase 01844114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docefrez
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
48
substance PinvestigationalPhase 4, Phase 3, Phase 221733507-63-036511, 44359816
Synonyms:
 
Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2
49Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 08496
50Gastrointestinal AgentsPhase 4, Phase 3, Phase 2, Phase 16401

Interventional clinical trials:

(show top 50)    (show all 5088)
idNameStatusNCT IDPhase
1Non-small Cell Lung Cancer RegistryCompletedNCT00099541Phase 4
2Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone MetastasisCompletedNCT00762346Phase 4
3Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese PopulationCompletedNCT02000531Phase 4
4Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)CompletedNCT00770588Phase 4
5Chemotherapy for Patients With Non-Small Cell Lung CancerCompletedNCT00380718Phase 4
6A Study in Non-squamous Non Small Cell Lung Cancer in Asian PatientsCompletedNCT01020786Phase 4
7A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung CancerCompletedNCT01196078Phase 4
8A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR MutationsCompletedNCT01287754Phase 4
9A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease ProgressionCompletedNCT01230710Phase 4
10Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving BisphosphonatesCompletedNCT00765687Phase 4
11Concurrent Chemoradiotherapy (CCRT) With Paclitaxel Plus Cisplatin in LA Non-small-cell Lung Cancer (NSCLC)CompletedNCT00686322Phase 4
12An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00949910Phase 4
13A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES)CompletedNCT00388206Phase 4
14Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During ChemotherapyCompletedNCT00115206Phase 4
15A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung CancerCompletedNCT01066884Phase 4
16Pemetrexed Followed by Docetaxel or in Reverse SequenceCompletedNCT01442909Phase 4
17Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLCCompletedNCT02497118Phase 4
18A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.CompletedNCT00451906Phase 4
19Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung CancerCompletedNCT00883675Phase 4
20A Study on the Long Term Survivals in an Expand Access Program (EAP) of IressaCompletedNCT01000740Phase 4
21Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer PatientsCompletedNCT01402089Phase 4
22Modafinil for the Treatment of Fatigue in Lung Cancer V9.0CompletedNCT00829322Phase 4
23A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR MutationsCompletedNCT01609543Phase 4
24SELINE: Second-Line Iressa Phase IV Study in NSCLC PatientsCompletedNCT00608868Phase 4
25Iressa Case Control Study in JapanCompletedNCT00252759Phase 4
26Dose Escalation Of Icotinib In Previously Treated Patients With Routine DoseCompletedNCT01465243Phase 4
27Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit SmokingCompletedNCT00365508Phase 4
28Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung CancerCompletedNCT01741506Phase 4
29"Red Morphine Drops" for Symptomatic Treatment of Dyspnoea in Lung CancerCompletedNCT00338481Phase 4
30Fentanyl Matrix in Lung Cancer PainCompletedNCT01060137Phase 4
31RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine DifferentiationCompletedNCT01317615Phase 4
32Carotene and Retinol Efficacy TrialCompletedNCT00712647Phase 4
33Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration for the Diagnosis of Hilar/Mediastinal LymphadenopathiesCompletedNCT01658280Phase 4
34Bio-Behavioral Lung Cancer Prevention ProgramCompletedNCT00322205Phase 4
35Anesthesia in Flexible Bronchoscopy for Lung Cancer DiagnosticCompletedNCT00440960Phase 4
36Staple-line Reinforcement for Prevention of Pulmonary Air LeakageCompletedNCT00925444Phase 4
37Cryospray Ablation of Surgical Resection Specimens To Determine Safety And Histological Effect In The LungCompletedNCT00747773Phase 4
38Fractionated Versus Target-controlled Propofol Administration in BronchoscopyCompletedNCT02246023Phase 4
39Ultrathin Bronchoscopy for Solitary Pulmonary NodulesCompletedNCT02490059Phase 4
40A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With CancerCompletedNCT00277160Phase 4
41Subcutaneous Amifostine Safety StudyCompletedNCT00158041Phase 4
42Antinociceptive Modalities on Ischemia Reperfusion InjuryCompletedNCT01932918Phase 4
43Comparison of the Ultra-low-dose Veo Algorithm With the Gold Standard Filtered Back Projection for Detecting Pulmonary Asbestos-related ConditionsCompletedNCT01955018Phase 4
44Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone TreatmentCompletedNCT01372904Phase 4
45Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical ResearchRecruitingNCT02513355Phase 4
46Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung CancerRecruitingNCT02031601Phase 4
47A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC)RecruitingNCT01028729Phase 4
48Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the ElderlyRecruitingNCT02151149Phase 4
49Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or OlderRecruitingNCT02514174Phase 4
50Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)RecruitingNCT02695290Phase 4

Search NIH Clinical Center for Lung Cancer

Inferred drug relations via UMLS65/NDF-RT43:


Cochrane evidence based reviews: carcinoma, non-small-cell lung

Genetic Tests for Lung Cancer

About this section

Genetic tests related to Lung Cancer:

id Genetic test Affiliating Genes
1 Adenocarcinoma of Lung, Somatic22 PARK2
2 Lung Cancer22 GSTM1
3 Lung Cancer, Somatic22 KRAS

Anatomical Context for Lung Cancer

About this section

MalaCards organs/tissues related to Lung Cancer:

33
Lung, Brain, Breast, Testes, Bone, Endothelial, Lymph node

FMA organs/tissues related to Lung Cancer:

16
The lung

Animal Models for Lung Cancer or affiliated genes

About this section

MGI Mouse Phenotypes related to Lung Cancer:

38 (show all 20)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000538412.0BRAF, CASP8, EGFR, ERBB2, ERCC6, FASLG
2MP:001076811.9BRAF, CASP8, EGFR, ERBB2, ERCC6, FASLG
3MP:000537611.9BRAF, CASP8, EGFR, ERBB2, ERCC6, FASLG
4MP:000200611.8BRAF, CASP8, EGFR, ERBB2, ERCC6, FASLG
5MP:001077111.8BRAF, CASP8, EGFR, ERBB2, ERCC6, FASLG
6MP:000363111.8BRAF, CASP8, EGFR, ERBB2, ERCC6, FASLG
7MP:000538511.7BRAF, CASP8, EGFR, ERBB2, FASLG, IRF1
8MP:000538811.7BRAF, CASP8, EGFR, ERBB2, FASLG, GNL3
9MP:000537811.7BRAF, CASP8, EGFR, ERBB2, ERCC6, GNL3
10MP:000537911.7BRAF, CASP8, EGFR, ERBB2, FASLG, IRF1
11MP:000538711.6BRAF, CASP8, EGFR, ERCC6, FASLG, IRF1
12MP:000537011.6BRAF, CASP8, EGFR, ERCC6, FASLG, KRAS
13MP:000536911.5BRAF, CASP8, EGFR, ERBB2, ERCC6, KRAS
14MP:000536711.5BRAF, CASP8, EGFR, FASLG, IRF1, KRAS
15MP:000538111.4BRAF, EGFR, ERBB2, FASLG, KRAS, MAP3K8
16MP:000539711.4BRAF, CASP8, EGFR, ERCC6, FASLG, IRF1
17MP:000539011.3BRAF, EGFR, ERBB2, ERCC6, FASLG, IRF1

Publications for Lung Cancer

About this section

Articles related to Lung Cancer:

(show top 50)    (show all 12359)
idTitleAuthorsYear
1
Significance of tumour cell HLA-G5/-G6 isoform expression in discrimination for adenocarcinoma from squamous cell carcinoma in lung cancer patients. (25689063)
2015
2
Efficacy and tolerability of crizotinib in the treatment of ALK-positive, advanced non-small cell lung cancer in Chinese patients. (25966792)
2015
3
Cyclic AMP signaling reduces sirtuin 6 expression in non-small cell lung cancer cells by promoting ubiquitin-proteasomal degradation via inhibition of the Raf-MEK-ERK (Raf/mitogen-activated extracellular signal-regulated kinase/extracellular signal-regulated kinase) pathway. (25713071)
2015
4
Low miR-145 expression level is associated with poor pathological differentiation and poor prognosis in non-small cell lung cancer. (25661374)
2015
5
Folate pathway gene MTHFR C677T polymorphism and risk of lung cancer in Asian populations. (25422209)
2014
6
Overexpression of collagen triple helix repeat containing 1 (CTHRC1) is associated with tumour aggressiveness and poor prognosis in human non-small cell lung cancer. (25238260)
2014
7
Group IIa secretory phospholipase A2 (sPLA2IIa) and progression in patients with lung cancer. (25317799)
2014
8
Can statins reduce risk of lung cancer, especially among elderly people? A meta-analysis. (24385695)
2013
9
Relationship between gene polymorphisms of two cytokine genes (TNF-I+ and IL-6) and occurring of lung cancers in the ethnic group Han of China. (23100065)
2013
10
let-7b and miR-126 are down-regulated in tumor tissue and correlate with microvessel density and survival outcomes in non--small--cell lung cancer. (23029111)
2012
11
Expression of heme oxygenase-1 in non-small cell lung cancer (NSCLC) and its correlation with clinical data. (22418244)
2012
12
Relationship among the expression of lymphatic vessel density, microvessel density, carcinoembryonic antigenic mRNA, KAI1, and Kiss-1, and prognosis in patients with non-small cell lung cancer]. (22681921)
2012
13
Structural basis of tumor suppressor in lung cancer 1 (TSLC1) binding to differentially expressed in adenocarcinoma of the lung (DAL- 1/4.1B). (21131357)
2011
14
Association of FOXP3 expression with non-small cell lung cancer. (21617226)
2011
15
P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment. (21616632)
2011
16
Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. (20828860)
2011
17
Expression and clinical relevance of uPA and ET-1 in non-small cell lung cancer]. (21219832)
2011
18
High temperature requirement A3 (HtrA3) promotes etoposide- and cisplatin-induced cytotoxicity in lung cancer cell lines. (20154083)
2010
19
XRCC1 polymorphisms and lung cancer risk in Chinese populations: a meta-analysis. (19329222)
2009
20
Breast cancer metastasis suppressor 1 (BRMS1) suppresses metastasis and correlates with improved patient survival in non-small cell lung cancer. (19111386)
2009
21
Age-associated changes of extracellular matrix collagen impair lung cancer cell migration. (19109409)
2009
22
Association of XPD polymorphisms with severe toxicity in non-small cell lung cancer patients in a Chinese population. (19458053)
2009
23
Proteomics and pathway analysis identifies JNK signaling as critical for high linear energy transfer radiation-induced apoptosis in non-small lung cancer cells. (19168796)
2009
24
Blazein of a new steroid isolated from Agaricus blazei Murrill (himematsutake) induces cell death and morphological change indicative of apoptotic chromatin condensation in human lung cancer LU99 and stomach cancer KATO III cells. (19020714)
2008
25
Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. (18854777)
2008
26
Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients. (18715616)
2008
27
Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. (18212743)
2008
28
Mediastinal lymphatic drainage from pulmonary lobe based on CT observations of histoplasmosis: implications for minimal N2 disease of non-small-cell lung cancer. (17952543)
2007
29
Serum level changes of matrix metalloproteinases 2 and 9, vascular endothelial growth factor and epidermal growth factor receptor during platinum-based chemotherapy in advanced non-small cell lung cancer patients. (17436410)
2007
30
In vitro simulation study of individualized chemotherapy in lung cancer. (17625370)
2007
31
Hypoxia-inducible factor-1alpha suppressing apoptosis and increasing tolerance of lung cancer cells to chemotherapy. (17219956)
2006
32
Enhanced expression of VEGF following bFGF inhibition in non-small cell lung cancer cell lines. (16934908)
2006
33
Consequences of chemoresistance for the herpes simplex virus thymidine kinase/ganciclovir-induced bystander effect in a human small cell lung cancer cell line model. (15816546)
2005
34
Serum carcinoembryonic antigen level in pN1 non-small cell lung cancer patients. (16101187)
2005
35
Role of IL-6 in neuroendocrine differentiation and chemosensitivity of non-small cell lung cancer. (15894559)
2005
36
Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells. (16170027)
2005
37
Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial. (15301877)
2004
38
Association between glutathione S-transferase p1 polymorphisms and lung cancer risk in Caucasians: a case-control study. (12660004)
2003
39
Induction of RECK by nonsteroidal anti-inflammatory drugs in lung cancer cells. (12447698)
2002
40
Association of L-myc polymorphism with lung cancer susceptibility and prognosis in relation to age-selected controls and stratified cases. (11955646)
2002
41
IL-12-induced production of IL-10 and interferon-gamma by mononuclear cells in lung cancer-associated malignant pleural effusions. (11804690)
2002
42
A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. (11691799)
2001
43
p21 is associated with cyclin D1, p16INK4a and pRb expression in resectable non-small cell lung cancer. (10762631)
2000
44
Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells. (10495436)
1999
45
MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. (9930070)
1998
46
Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. (9036871)
1997
47
Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. (9228385)
1997
48
Phase I study of cisplatin, ifosfamide and CPT11 with granulocyte colony-stimulating factor support in advanced non-small cell lung cancer]. (8831740)
1996
49
Altered HLA class I expression in non-small cell lung cancer is independent of c-myc activation. (1849792)
1991
50
Epidemiologic and histologic observations on lung cancer in pneumoconiosis population. (7172143)
1982

Variations for Lung Cancer

About this section

UniProtKB/Swiss-Prot genetic disease variations for Lung Cancer:

67
id Symbol AA change Variation ID SNP ID
1BRAFp.Gly466ValVAR_018512
2BRAFp.Leu597ArgVAR_018513
3MXRA5p.Ser862AsnVAR_072408
4SLC22A18p.Ser233PheVAR_024062

Clinvar genetic disease variations for Lung Cancer:

5
id Gene Variation Type Significance SNP ID Assembly Location
1KRASNM_033360.3(KRAS): c.34G> T (p.Gly12Cys)single nucleotide variantPathogenicrs121913530GRCh37Chr 12, 25398285: 25398285
2BRAFNM_004333.4(BRAF): c.1789C> G (p.Leu597Val)single nucleotide variantPathogenicrs121913369GRCh37Chr 7, 140453146: 140453146
3EGFRNM_005228.3(EGFR): c.2126A> G (p.Glu709Gly)single nucleotide variantdrug responsers397517085GRCh37Chr 7, 55241678: 55241678
4KRASNM_004985.4(KRAS): c.179G> T (p.Gly60Val)single nucleotide variantLikely pathogenic, Pathogenicrs727503108GRCh37Chr 12, 25380279: 25380279
5PPP2R1BNM_181699.2(PPP2R1B): c.269G> A (p.Gly90Asp)single nucleotide variantPathogenicrs1805076GRCh37Chr 11, 111635566: 111635566
6SLC22A18NM_183233.2(SLC22A18): c.698C> T (p.Ser233Phe)single nucleotide variantPathogenicrs121909071GRCh37Chr 11, 2939260: 2939260

Cosmic variations for Lung Cancer:

7 (show top 50)    (show all 1462)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1COSM444BRAFlung,NS,carcinoma,adenocarcinoma64
2COSM446BRAFlung,NS,carcinoma,adenocarcinoma64
3COSM451BRAFlung,NS,carcinoma,adenocarcinoma64
4COSM459BRAFlung,NS,carcinoma,adenocarcinoma64
5COSM460BRAFlung,NS,carcinoma,adenocarcinoma64
6COSM467BRAFlung,NS,carcinoma,adenocarcinoma64
7COSM470BRAFlung,NS,carcinoma,adenocarcinoma64
8COSM471BRAFlung,NS,carcinoma,adenocarcinoma64
9COSM476BRAFlung,NS,carcinoma,adenocarcinoma64
10COSM498HRASlung,NS,carcinoma,adenocarcinoma64
11COSM509KRASlung,NS,carcinoma,adenocarcinoma64
12COSM511KRASlung,NS,carcinoma,adenocarcinoma64
13COSM516KRASlung,NS,carcinoma,adenocarcinoma64
14COSM517KRASlung,NS,carcinoma,adenocarcinoma64
15COSM518KRASlung,NS,carcinoma,adenocarcinoma64
16COSM520KRASlung,NS,carcinoma,adenocarcinoma64
17COSM521KRASlung,NS,carcinoma,adenocarcinoma64
18COSM522KRASlung,NS,carcinoma,adenocarcinoma64
19COSM523KRASlung,NS,carcinoma,adenocarcinoma64
20COSM527KRASlung,NS,carcinoma,adenocarcinoma64
21COSM528KRASlung,NS,carcinoma,adenocarcinoma64
22COSM529KRASlung,NS,carcinoma,adenocarcinoma64
23COSM532KRASlung,NS,carcinoma,adenocarcinoma64
24COSM534KRASlung,NS,carcinoma,adenocarcinoma64
25COSM541KRASlung,NS,carcinoma,adenocarcinoma64
26COSM542KRASlung,NS,carcinoma,adenocarcinoma64
27COSM549KRASlung,NS,carcinoma,adenocarcinoma64
28COSM552KRASlung,NS,carcinoma,adenocarcinoma64
29COSM554KRASlung,NS,carcinoma,adenocarcinoma64
30COSM561NRASlung,NS,carcinoma,adenocarcinoma64
31COSM562NRASlung,NS,carcinoma,adenocarcinoma64
32COSM563NRASlung,NS,carcinoma,adenocarcinoma64
33COSM564NRASlung,NS,carcinoma,adenocarcinoma64
34COSM565NRASlung,NS,carcinoma,adenocarcinoma64
35COSM580NRASlung,NS,carcinoma,adenocarcinoma64
36COSM583NRASlung,NS,carcinoma,adenocarcinoma64
37COSM584NRASlung,NS,carcinoma,adenocarcinoma64
38COSM707METlung,NS,carcinoma,adenocarcinoma64
39COSM759PIK3CAlung,NS,carcinoma,adenocarcinoma64
40COSM760PIK3CAlung,NS,carcinoma,adenocarcinoma64
41COSM763PIK3CAlung,NS,carcinoma,adenocarcinoma64
42COSM766PIK3CAlung,NS,carcinoma,adenocarcinoma64
43COSM775PIK3CAlung,NS,carcinoma,adenocarcinoma64
44COSM776PIK3CAlung,NS,carcinoma,adenocarcinoma64
45COSM1125BRAFlung,NS,carcinoma,adenocarcinoma64
46COSM5038PTENlung,NS,carcinoma,adenocarcinoma64
47COSM5049PTENlung,NS,carcinoma,adenocarcinoma64
48COSM5062PTENlung,NS,carcinoma,adenocarcinoma64
49COSM5111PTENlung,NS,carcinoma,adenocarcinoma64
50COSM5120PTENlung,NS,carcinoma,adenocarcinoma64

Expression for genes affiliated with Lung Cancer

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Lung Cancer patients vs. healthy controls: 32 (show all 216)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1SFTPCsurfactant protein CLung-6.580.000
2CLDN18claudin 18Lung-6.410.000
3ADH1Balcohol dehydrogenase 1B (class I), beta polypeptideLung-6.180.000
4KRT6Akeratin 6A, type IILung+5.850.000
5AGERadvanced glycosylation end product-specific receptorLung-5.700.000
6MMP12matrix metallopeptidase 12Lung+5.630.000
7CLIC5chloride intracellular channel 5Lung-5.510.000
8AQP4aquaporin 4Lung-5.290.000
9CYP4B1cytochrome P450, family 4, subfamily B, polypeptide 1Lung-5.270.000
10SPRR1Bsmall proline-rich protein 1BLung+5.250.000
11AKR1B10aldo-keto reductase family 1, member B10 (aldose reductase)Lung+5.160.000
12